Progression in melanoma:considerations and implictions in dissecting nodal fields by Wevers, Kevin Patrick
  
 University of Groningen
Progression in melanoma
Wevers, Kevin Patrick
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2013
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Wevers, K. P. (2013). Progression in melanoma: considerations and implictions in dissecting nodal fields.
Groningen: s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Progression in Melanoma 
Considerations and Implications in Dissecting Nodal Fields
Kevin P. Wevers 
2013
The printing of this thesis was financially supported by:











Progression in melanoma: considerations and implications in dissecting nodal fields
Thesis, University of Groningen, the Netherlands
ISBN:  978-90-367-6190-1
ISBN:  978-90-367-6189-5 (E-book)
© Copyright 2013 Kevin Patrick Wevers, the Netherlands
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or transmitted 
in any form or by any means, without prior permission of the author. 
Cover:   K.P. Wevers
Lay out:   M.R. Wevers
Printed by: Drukwerkconsultancy, Utrecht
Progression in Melanoma 
Considerations and Implications in Dissecting Nodal Fields
Proefschrift
ter verkrijging van het doctoraat in de 
Medische Wetenschappen 
aan de Rijksuniversiteit Groningen 
op gezag van de 
Rector Magnificus, dr. E. Sterken, 
in het openbaar te verdedigen op 
woensdag 19 juni 2013
om 16.15 uur
door
Kevin Patrick Wevers 
geboren op 30 augustus 1985 
te Nijmegen
Promotor:    Prof. dr. H.J. Hoekstra
Beoordelingscommissie:  Prof. dr. I.H.M. Borel Rinkes 
     Prof. dr. W.T.A. van der Graaf 
     Prof. dr. A.J.H. Suurmeijer    
    
Paranimfen:   Faas Dolmans 

















General introduction and outline of thesis
Early mobilization after ilio-inguinal lymph node dissection for 
melanoma does not increase the wound complication rate
Predictive factors that enable patient selection for completion 
lymph node dissection
Assessment of a new scoring system for predicting non-sentinel node 
positivity in sentinel node-positive melanoma patients
Serum S-100B levels are associated with non-sentinel node positivity 
in 68 sentinel node-positive melanoma patients
Melanoma follow-up and prognostic factors in surgery for nodal 
recurrences
Cutaneous melanoma: medical specialists’ opinions on follow-up and 
sentinel lymph node biopsy
Therapeutic lymph node dissection in melanoma: different prognosis 
for different macrometastasis sites?
S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C 
melanoma
Feasibility of complete resection in stage IV melanoma
Stage IV melanoma: completely resectable patients are scarce
Summary and conclusions





























Cutaneous melanoma, which is the most malignant skin cancer type, has got one of the fastest 
increasing incidence rates of all cancers in the western world. In the Netherlands, its incidence has 
more than doubled over the past two decades, from 11.3 per 100,000 in 1989 to 28.1 per 100,000 in 
2010.1, 2 In 2013, roughly 5000 people in the Netherlands and 70,000 in the United States of America 
will be diagnosed with melanoma.1  Although nearly half of these patients will present with thin 
melanomas (Breslow thickness < 1.0mm)3, one out of every five patients will die due to progression of 
their cutaneous melanoma.1 
Staging
Most melanoma patients initially present with clinically localized disease (stage I and II). The most 
important predictors of outcome in such patients are Breslow thickness, ulceration, and the mitotic 
rate of the primary tumor.3, 4 The sentinel lymph node status, determined by sentinel lymph node 
biopsy (SLNB), is also of great importance for prognosis and in most studies this represents the 
strongest predictor of outcome.5 These pathologic characteristics form the backbone of the 7th 
melanoma staging manual developed by the American Joint Committee on Cancer (AJCC) in 2009 
(Table 1 and 2).3
 Melanomas most frequently metastasize to the regional lymph nodes, before distant sites become 
involved.6 When metastases in regional lymph nodes are found, either by SLNB (micrometastases) or 
by analysis of a clinically palpable lymph node (macrometastases), the patient is classified as stage III. 
Stage IV melanoma describes metastatic disease at distant sites, categorized according to location of 
metastasis and serum Lactate Dehydrogenase (LDH) level. 
Treatment of the primary cutaneous melanoma
Local treatment for the primary melanoma consists of surgical excision with melanoma free margins. 
The recommended margin of a therapeutic re-excision depends on the Breslow thickness of the 
melanoma and amounts 1 cm for melanoma < 2.0 mm and 2 cm for melanoma > 2.0 mm.7 
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Table 1. TNM staging categories for cutaneous melanoma
Tumor Breslow thickness Ulceration / mitotic rate
T1 ≤1.0 mm T1a: Without ulceration and 
mitosis <1/mm2 
T1b: With ulceration and mitosis 
≥1/mm2
T2 1.01-2.0 mm T2a: Without ulceration
T2b: With ulceration
T3 2.01-4.0 mm T3a: Without ulceration 
T3b: With ulceration
T4 >4.0 mm T4a: Without ulceration
T4b: With ulceration
Node No. of metastatic nodes Nodal metastatic burden*
N0 0
N1 1 N1a: Micrometastasis
N1b: Macrometastasis
N2 2-3 N2a: Micrometastases
N2b: Macrometastases
N2c: In transit metastases/
satellites without 
metastatic nodes
N3 4+ metastatic nodes, matted nodes, or 
in transit metastases/satellites with 
metastatic nodes
Metastasis Site Serum LDH
M0 No distant metastasis
M1a Distant skin, subcutaneous, or nodal metastases Normal LDH
M1b Lung metastases Normal LDH




* Micrometastases are diagnosed through sentinel lymph node biopsy. Macrometastases are defined as 
clinically detectable nodal metastases confirmed pathologically. 
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Table 2. Anatomic stage groupings for melanoma
Clinical Staging* Pathologic Staging*
T N M T N M
IA T1a N0 M0 IA T1a N0 M0
IB T1b N0 M0        IB T1b N0 M0
T2a N0 M0 T2a N0 M0
IIA T2b N0 M0 IIA T2b N0 M0
T3a N0 M0 T3a N0 M0
IIB T3b N0 M0 IIB T3b N0 M0
T4a N0 M0 T4a N0 M0
IIC T4b N0 M0 IIC T4b N0 M0
III Any T N1-3 M0 IIIA T1-4a N1a M0
T1-4a N2a M0





IIIC T1-4b N1b M0
T1-4b N2b M0
T1-4b N2c M0
Any T N3 M0
IV Any T Any N M1 IV Any T Any N M1
* Clinical staging includes microstaging of the primary melanoma and clinical/
radiologic evaluation for metastases. By convention, it should be used after 
complete excision of the primary melanoma with clinical assessment for 
regional and distant metastases. Pathologic staging includes microstaging of 
the primary melanoma and pathologic information about the regional lymph 
nodes after partial (ie, sentinel node biopsy) or complete lymphadenectomy. 
Pathologic stage 0 or stage IA patients are the exception; they do not require 
pathologic evaluation of their lymph nodes.
Chapter 1 
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Sentinel lymph node biopsy and completion lymph node dissection
Because cutaneous melanomas predominantly progress through draining afferent lymph vessels and 
corresponding lymph nodes (Figure 1), a lot of research is focused on removing occult metastases in 
regional lymph nodes by dissection of the nodal basin. 
 Elective regional lymph node dissection for localized melanoma without clinical evidence of 
metastatic spread was abandoned in the nineties, as it resulted in substantial morbidity (wound 
infections, seroma, and lymphedema) and increased survival only in one out of five patients who 
had nodal micrometastasis.8 Searching for a way to identify these patients with clinically occult nodal 
metastasis, D.L. Morton introduced the SLNB for melanoma9 and studied it in the first Multicenter 
Selective Lymphadenectomy Trial (MSLT-I). The SLNB uses a radioactive tracer and a blue dye to identify 
the lymph node in the regional lymph node basin to which the cutaneous afferent lymphatic vessels 
drain first and which is most likely the first site to contain metastases (Figure 2).10-12 Awaiting the final 
results after completion of the MSLT-I follow-up, it was already shown that the sentinel node status is 
a very important prognostic factor in patients with clinically localized melanoma.5, 13 Moreover, the last 
interim analysis of the MSLT-I suggested that SLNB, followed by immediate completion lymph node 
dissection (CLND) if micrometastases are found, leads to an improved melanoma specific survival.14 
Until the final results of MSLT-I are available, most countries use the SLNB as a staging procedure in 
patients with melanomas > 1 mm Breslow thickness or < 
1 mm in case of present ulceration or high mitotic rate. 
 In sentinel-node positive patients, it is currently 
recommended to perform a CLND.15 However, metastatic 
involvement in so called non-sentinel nodes is found 
in only 20% on histopathological analysis of the CLND 
specimens. In other words, roughly 4 out of 5 patients 
will not have affected regional nodes apart from the 
positive sentinel node. CLND in these patients causes 
unnecessary morbidity and economic burden. Currently 
pending international trials are studying alternative 
treatment regimens for sentinel-node positive patients. 
The second Multicenter Selective Lymphadenectomy 
Trial (MSLT-II) by Morton et al.16 compares CLND with 
nodal observation using ultrasound and performing a 
therapeutic lymph node dissection (TLND) only if nodal 
metastases become clinically manifest. The EORTC 
MINITUB registration study17 explores the efficacy of 
CLND omission in patients with minimal tumor burden
in the sentinel node.  
Figure 1. Draining lymph node basins in 
groin, axilla, and neck




The overall prevalence of cancer patients continues to increase due to rising incidence rates and 
improved treatment outcomes. Also in melanoma, this has resulted in a rising demand on health care 
resources with more and more patients needing treatment and subsequent follow-up visits.18 The 
frequency of follow-up visits has been widely debated for melanoma, but neither scientific evidence 
nor international consensus does exist. Overall, high frequency follow-up is currently recommended 
in countries with the highest melanoma incidence.19 In order to establish an evidence based follow-
up schedule for melanoma patients, our center prospectively studies the feasibility and safety of a 
reduced follow-up schedule in the pending multicenter MELFO trial.20, 21
 
Nodal and distant metastases 
Unfortunately, 16–28% of melanoma patients develop recurrent disease. These recurrences occur 
locally or in-transit in 20–28%, distant in 15–50%, but most frequently in regional lymph nodes (26–
60%).6 In case of a clinically manifest recurrence in the regional lymph node basin, whole-body FDG/
PET and / or spiral CT scanning increase the accurateness of staging by 27% upstaging to stage IV 
disease.22 Patients in whom metastatic spread is radiographically limited to the regional lymph nodes 
(stage IIIB-C) can be treated by a therapeutic lymph node dissection with curative intent. The overall 
5-year survival of these patients is 29–52%.3, 8, 23-26 
 Melanoma patients who develop distant metastases (stage IV) suffer a very poor prognosis. The 
one-year survival rate varies between 33% and 66%, depending on LDH level and the location of the 
metastases.3 Different treatment strategies are possible. 
 In previous studies, the best survival rates were found for stage IV patients who underwent 
complete surgical removal, i.e. total resection of all radiographic and clinical evident metastases. 
Small retrospective series established that patients in whom complete surgical removal is feasible 
have a 5-year survival rate of 15-28%27-32, which is superior to 5-10% found for patients who receive 
systemic medical therapy33, 34. The prospective series of the Southwest Oncology Group showed a 
Figure 2. Lymphoscintigraphy and intracutaneous injection of blue dye to identify and 
remove the sentinel lymph node
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25% 5-year survival in 64 patients who had their metastases completely resected35.  Even better 
survival rates were found during the MMAIT-IV trial which combined surgery with immunotherapy: 
5-year survival 40-45%36. These results suggest that surgery should be the first choice of treatment for 
stage IV melanoma whenever complete surgical removal is feasible. However, recent breakthroughs 
in systemic medical therapy with ipilimumab and BRAF inhibitors like vemurafenib have also shown 
some promising results.37, 38 Recently, a randomized controlled trial was initiated to compare complete 
surgical removal and systemic medical therapy as initial treatment for completely resectable stage IV 
melanoma.39
Biomarkers in melanoma
In general, tumor biomarkers can be used for primary screening, as a diagnostic tool, for staging, as a 
prognostic marker, to evaluate the effect of treatment, and to screen for recurrences in follow-up. In 
melanoma, two biomarkers have been extensively studied: earlier LDH and lately S-100B.40 LDH was 
implemented in the AJCC system in 2001 only to classify stage IV patients. The melanoma associated 
molecule S-100B was found to be correlated with melanoma progression in both stage III and IV 
disease.41, 42 However, in the United States the biomarker S-100B is rarely used in melanoma research 
and not widely accepted in melanoma care. In contrast, in Europe the marker, which seems to reflect 




Cutaneous melanoma is characterized by the unbelievably unpredictable arise of distant metastases. 
However, in contrast to most solid tumors, melanomas show an orderly and predictable nodal 
metastatic pattern. Improvements in the balance between radical surgical removal of potentially 
affected lymph nodes and the substantial morbidity and costs this surgery entails should be sought in 
better patient selection. First, the incidence of and risk factors for complications in ilio-inguinal lymph 
node dissections in both sentinel node positive patients and patients with palpable nodal metastases 
are described (chapter 2). Then, Part I – Predictive factors that enable patient selection for completion 
lymph node dissection focuses on the selection of high risk sentinel-node positive patients for CLND 
using histopathologic characteristics and melanoma biomarkers. 
 The increasing prevalence of melanoma patients causes a rising demand on healthcare resources. 
This leads to a stunning increase in follow-up visits, as high-frequency follow-up is practiced in many 
countries. Part II – Melanoma follow-up and prognostic factors in surgery for nodal recurrences 
discusses medical specialists’ opinions on optimal melanoma follow-up and reveals prognostic factors 
that could improve staging and patient selection for (neo)adjuvant therapies in patients with palpable 
nodal recurrences. This accurate patient selection is needed in order to apply new systemic medical 
agents as (neo)adjuvant therapies, without inducing excessive morbidity and costs. 
 Part III – Feasibility of complete resection in stage IV melanoma studies the proportion of 
melanoma patients in which complete surgical resection of all distant metastases at stage IV diagnosis 
is achievable.
18
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Chapter 2
Early mobilization after ilio-inguinal lymph node dissection for 
melanoma does not increase the wound complication rate
K.P. Wevers, H.P.A.M. Poos, R.J. van Ginkel, B. van Etten, H.J. Hoekstra
Eur J Surg Oncol. 2013 Feb;39(2):185-90.
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ABSTRACT
Aim. Ilio-inguinal lymph node dissection for stage III melanoma is accompanied by a substantial 
amount of wound complications. Our treatment protocols changed in time in terms of postoperative 
bed rest prescriptions, being in chronological order Group A: 10 days with a Bohler Braun splint, Group 
B: 10 days without splint, and Group C: 5 days without splint. The aim of this study was to evaluate the 
effect of bed rest prescriptions on wound complications.
Methods. For this study, we included all patients who underwent ilio-inguinal dissection for stage 
III melanoma in the period 1989-2011. Both univariate and multivariable analysis were performed 
to identify factors that were associated with occurrence of wound complications defined as wound 
infection, wound necrosis, and seroma.
Results. Of the 204 patients analyzed, 99 suffered one or more wound complications: 51 wound 
infection, 29 wound necrosis, and 39 seroma. A wound complication occurred in 26 out of 64, 51 out 
of 89, and 22 out of 51 patients for Group A, B, and C, respectively. Univariate analysis showed age 
>55 (p=0.001) and presence of comorbidity (p=0.002) to be associated with higher incidence of wound 
complications. The 5 day bed rest protocol used in group C did not significantly increase the incidence 
of wound complications (ref=Group A: OR=1.18; 95%CI=0.52-2.68, p=0.698).
Conclusion. Early mobilization did not significantly increase the overall wound complication rate 





The incidence of melanoma is constantly increasing in the western world. In the Netherlands the 
incidence doubled in the past two decades, from 11.3 per 100 000 in 1989 to 26.3 per 100 000 in 
2009.1, 2 Most of the patients present initially with Stage I or II melanoma.3 Unfortunately, despite 
defined surgical treatment of the primary melanoma with excision margins of 1 or 2 cm, approximately 
16-28% will develop recurrent disease. These recurrences occur in 20-28% local or in-transit, 15-50% 
on distant sites, but most frequently in regional lymph nodes (26-60%).4 
 For nodal metastases in the groin region, ilio-inguinal lymph node dissection is performed. 
Both clinically detectable nodal metastases (macrometastasis) and a positive sentinel lymph node 
biopsy (micrometastasis) identified by hematoxylin and eosin staining reflect nodal disease and are 
indications for an ilio-inguinal lymph node dissection in our center. These procedures for stage III 
melanoma are accompanied by a substantial amount of wound complications, with complication rates 
up to almost 50% in literature.5-8 
 Our treatment protocols for ilio-inguinal lymph node dissection changed in time in terms of 
postoperative bed rest prescriptions. In the beginning a 10 day long period of strict bed rest with the 
usage of a Bohler Braun splint was thought to prevent complications by reducing edema and tension 
along the wound. Later, with the introduction of adjustable hospital beds the Bohler Braun splint was 
abandoned, although the duration of prescribed bed rest remained 10 days. In this period more wound 
healing problems seemed to occur7. The protocol was adjusted to prescription of 5 days of bed rest in 
the most recent period following studies that successfully handled early mobilization6, 9. Grounds for 
this adjustment were increasing cost effectiveness as well as the conviction 10 days of bed rest would 
not improve wound healing and could increase the risk for complications like deep venous thrombosis 
and pulmonary embolism. This resulted in three consecutive cohorts being in chronological order 
Group A: 10 days with a Bohler Braun splint, Group B: 10 days without splint, and Group C: 5 days 
without splint. The aim of this study was to evaluate the effect of bed rest prescriptions on early 
wound complications.
Patients and methods
Patients and data acquisition
For this retrospective study we included all patients who underwent ilio-inguinal dissection for stage III 
melanoma for both clinically detectable macrometastasis and micrometastasis found by sentinel node 
biopsy in our center during the period 1989 to 2011. Patients who underwent a superficial dissection 
solely or in whom additional adjuvant limb perfusion was performed were excluded. Eventually, 204 
melanoma patients were analyzed in present study. 
 Characteristics of patient, primary melanoma, operative procedure, and postoperative period 
were recorded. Early wound complications were defined as complications within 30 days of the 
operative procedure and were divided into wound infection, wound necrosis and seroma. Wound 
24
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infection was scored if the wound was opened to drain an abscess, antibiotics were administered, 
or a positive culture was found. Wound necrosis was defined as necrotic edges of the wound which 
necessitated secondary wound healing for closure. Seroma was recorded when a puncture was 
performed. 
Surgical procedure
For ilio-inguinal dissection, the superficial lymph nodes as well as the iliac and obturator lymph 
nodes were excised via a single ellipse shaped incision. The sartorius muscle was used to cover the 
neurovascular femoral bundle, as described extensively in the past.7, 10 Since 2004, a single gift of 
antibiotic prophylaxis was given before the procedure to patients in whom sentinel node biopsy was 
performed previously. This was introduced to handle the increased risk for wound infection that was 
found in patients in whom lymph node dissection was performed after sentinel lymph node biopsy.11
 All patients were ordered strict bed rest with flexion in hip and knee for a minimum of 5 days, 
depending on the applicable protocol at time of surgical procedure. Flexion in hip and knee in all 
patients was provided by the Bohler Braun splint or later by the adjustable hospital beds. Support 
stockings were used for mobilization during the first 6 months and low molecular weight heparin 
was given until the patient was completely mobilized. Drains were removed after 10 days when the 
production was less than 20 ml a day. For patients with 5 days of bed rest drains were mostly removed 
in the outpatient department. 
Statistical analysis
Frequencies and percentages were used for description of patient and group characteristics. Differences 
between bed rest groups A, B, and C were analyzed by Fischer’s exact test or the chi-square test for 
categorical variables and the Kruskal-Wallis test for continuous variables, all on a 5% significance level. 
Association of variables with early complications was assessed by univariate and multivariable logistic 
regression analyses. All variables significant on a 20% significance level in univariate analysis were 
entered in the multivariable analysis to identify factors that were independently associated with early 
complications with a p<0.050.
Results
In total, we studied 204 patients, consisting of 105 females and 99 males with a median age of 56 
(range 5-91) years. The indication for ilio-inguinal dissection was clinically detected macrometastasis 
in 152 cases and metastasis found by sentinel lymph node biopsy in 52 patients. More than half of 
patients (n=110) had a Body Mass Index (BMI) over 25, 58 patients were smokers, and 12 had Diabetes 
Mellitus.  (Table 1)
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 As shown in table 2, differences in the bed rest groups were the median operative time, the 
operation year, and median hospital stay. The median time of procedures for patients in Group C was 
165 (range 110-290) minutes versus 130 (range 40-280) and 150 (range 75-290) minutes (p<0.001) for 
patients in Group A and B, respectively.
 The median hospital stay was significantly shorter in group C, being 7 (range 5-22) days compared 
to 14.5 (range 7-34) days in group A and 13 (range 8-45) days in group B (p<0.001). There were no 
statistically significant differences between 
the three groups for age, gender, smoking, 
BMI, diabetes mellitus, total comorbidity, and 
indication for the procedure.
Early wound complications
Overall, 99 patients suffered one or more 
wound complications. A wound infection 
occurred in 51 patients, wound necrosis was 
seen in 29 patients, and a seroma puncture 
was performed in 39 patients. 
 One or more wound complications 
occurred in 26 out of 64, in 51 out of 89, and 
in 22 out of 51 patients for Group A, B, and C 
(p=0.085), respectively. Multivariable analysis 
revealed age >55 (OR=2.25; 95%CI=1.19-4.25, 
p=0.01) and bed rest Group B (ref=Group A: 
OR=2.72; 95%CI=1.32-5.61, p=0.007) to be 
independently associated with occurrence of 
one or more wound complications. The rate of 
one or more complications in Group C did not 
significantly differ from the reference Group A 
(OR=1.18; 95%CI=0.52-2.68, p=0.698). (Table 
3) There were no significant differences for 
occurrence of wound infections and seroma 
in the bed rest groups. Wound necrosis was 
most frequently seen in Group B. (Table 3) 
Table 1. Patient characteristics of 204 ilio-inguinal lymph 
node dissections for stage III melanoma
Characteristic n (%)
Gender 






Age, in years, median (range) 56 (5-91)
Breslow thickness (mm)
  T1: ≤1.00 
  T2: 1.01-2.0 
  T3: 2.01-4.0
  T4: >4.0
  Unknown primary 














  Present 
  Absent





















Risk  factors 
  BMI > 25
  Smoking










Abbreviation: BMI, body mass index
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In multivariable analysis, higher BMI was associated with the occurrence of wound infections 
(p=0.018). For wound necrosis, the bed rest group was the only factor associated in multivariable 
analysis, showing more wound necrosis in Group B (p=0.004). No variable was significantly associated 
with occurrence of seroma in multivariable analysis. (Table 3)
Table 2. Comparison of clinicopathological characteristics between bed rest groups
Characteristic Group A
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  Median (range) 14.5 (7-34) 13 (8-45) 7 (5-22) <0.001
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Discussion
In the present study, early mobilization after 5 days following ilio-inguinal dissection for stage III 
melanoma did not increase the wound complication rate. We found both 10 days bed rest without 
usage of a Bohler Braun splint and age above 55 years to be associated with a higher occurrence of one 
or more wound complications. The early complication rate of 99 out of 204 found in this study is within 
the range of complication rates reported in literature for ilio-inguinal dissections.5-8 
Bed rest protocols
Bed rest of 10 days with usage of a Bohler Braun splint was associated with the lowest overall 
complication rate: in group A 26 out of 64 patients had one or more complications. The most recent 
5 day bed rest regimen currently used in our center (group C) did not show a significant increase, 
compared to group A, in early wound complication rate (22 out of 51 patients; OR=1.18; 95%CI=0.52-
2.68). A 10 day bed rest without the usage of a splint (group B) resulted in a significantly higher 
complication rate compared to group A (51 out of 89 patients; OR=2.72 95%CI=1.32-5.61). (Table 3) 
The higher complication rate found for group B was mostly formed by the high rate of wound necrosis 
in this group, with unknown cause. Although the exact reasons for the differences in complication 




The increased risk for wound infections with a high BMI is well known for many surgical procedures 
as well as for groin dissections in melanoma patients.12-14 The wound infection rate in this study was 
increased in patients who had overweight (BMI > 25) and was even higher in patients who were obese 
(BMI > 30). In patients with a sentinel node biopsy preceding the ilio-inguinal dissection, 16 out of 52 
suffered a wound infection compared to 35 out of 152 patients operated on for a macrometastasis 
(p=0.266). This wound infection rate for patients operated on for a positive sentinel node was not 
reduced despite of the perioperative antibiotic prophylaxis administered since 2004 in our center.11 
The wound necrosis rate was significantly lower in the 5 day bed rest group. Seroma was more 
frequently seen in diabetic patients (34 out of 192 vs 5 out of 12 in non-diabetics), although this was 
only significant in univariate analysis. 
Future perspectives 
The results of this study show that reducing the prescribed days of bed rest from 10 to 5 days after 
ilio-inguinal dissection for melanoma is feasible and does not significantly increase the early wound 
complication rate. Moreover, a 5 day bed rest regimen was associated with a significantly shorter 
hospital stay and could therefore contribute to increase cost-effectiveness of this surgical procedure. 
Moreover, early mobilization of patients will reduce morbidity related to prolonged immobility 
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(like venous thromboembolic events), although our cohort was too small to study these specific 
complications. In the future, even further reducing bed-rest and hospital day could be explored. 
Because no scientific data is available, we would recommend studying complication rates after 3 days 
of bed rest, before further reducing bed rest protocols. In our opinion a Bohler Braun splint is obsolete 
and patients often experience discomfort. Therefore we discourage its use in future practice. 
 
Limitations
Limitations of this study are associated with its retrospective character. Although complications seen in 
the outpatient department within 30 days were included in the analysis, there could have been under-
registration of minor complications, especially in the 5 day bed rest group. Maybe, this phenomenon 
accounts for the differences in wound necrosis rates between group B and C. 
 Some other centers may already mobilize their patients after 3, 2, or even one day, which could 
make the results of the present study not applicable to their situation. However, we feel that reducing 
bed rest to only 3 or less days can only be justified after monitoring complication rates after previous 
changes in bed rest protocols, as presented in this study. 
Conclusions
Overall, an ilio-inguinal dissection is a demanding procedure requiring ‘surgical skills’ to reduce the 
overall complication rate, which is probably caused by impaired arterial blood supply through to 
thin skin flaps. In this study, older age, prolonged bed rest without Bohler Braun splint usage and 
higher BMI were independently associated with a complicated course following ilio-inguinal lymph 
node dissection for melanoma. Changing ‘bed rest protocols’ to 5 days without Bohler Braun splint 
usage, did not significantly increase the incidence of complications. The application of a short bed 
rest protocol could possibly increase cost-effectiveness of the ilio-inguinal lymph node dissection for 
melanoma. 
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ABSTRACT
Background. When completion lymph node dissection (CLND) is performed in sentinel node (SN)-
positive melanoma patients, a positive non-sentinel node (NSN) is found in approximately 20% of 
them. Recently, Murali et al. proposed a new scoring system (non-sentinel node risk score, N-SNORE) 
to predict the risk of NSN positivity in SN-positive patients. The objectives of the current study were to 
identify factors predicting NSN positivity and to assess the validity of the N-SNORE in an independent 
patient cohort.
Methods. All SN-positive patients who underwent CLND at a single institution between 1995 and 
2010 were analyzed. Characteristics of the patient, primary melanoma, and SN(s) were tested for 
association with NSN positivity. Missing values were reconstructed using multiple imputation to 
enable multivariable analysis. 
Results. CLND revealed positive NSNs in 30 (23%) of 130 SN-positive patients. Primary melanoma 
regression (p=0.03) was independently associated with NSN positivity. After adjustment because of 
missing data on perinodal lymphatic invasion, N-SNORE proved to be a significant stratification model 
in our patient cohort (p=0.003): 5.9% NSN positivity in the very low risk category and 75.0% NSN 
positivity in the very high risk category. 
Conclusions. Presence of regression in the primary melanoma was independently associated 
with a higher risk of NSN positivity. The slightly modified N-SNORE scoring system provided useful 
stratification of the risk for NSN positivity. However, lack of perinodal lymphatic invasion data may 




The incidence of melanoma is steadily increasing in the Western world. In the Netherlands its incidence 
has more than doubled in the past two decades, from 11.3 per 100,000 in 1989 to 26.3 per 100,000 
in 2009.1, 2 In the United States the incidence rate in 2007 was 18.7 per 100,000 and it is estimated 
that more than 70,000 people will be diagnosed with melanoma in 2012.3, 4 Most melanoma patients 
in Western countries present initially with American Joint Committee on Cancer (AJCC) Stage I or II 
melanoma and 33-50% of these patients are diagnosed with Stage IA disease.1, 5
 The most important predictors of outcome in melanoma patients with clinically localized disease 
are Breslow thickness, ulceration, and the mitotic rate of the primary tumor.5, 6 The sentinel lymph 
node (SN) status, determined by sentinel lymph node biopsy (SLNB), is also of great importance for 
prognosis and in most studies this represents the strongest predictor of outcome.7 Furthermore, 
patients undergoing SLNB, with completion lymph node dissection (CLND) if metastatic nodal disease 
is identified, seem to have better regional tumor control and survival according to the most recent 
interim analysis of the first Multicenter Selective Lymphadenectomy Trial (MSLT-I).8
 Although CLND is usually performed in patients with a positive SN, one or more positive non-
sentinel nodes (NSNs) are found in only 8-33 % of patients undergoing CLND.7, 9, 10 In other words, 
approximately 4 out of every 5 SN-positive patients who receive a CLND will not have additional 
involved regional nodes identified. In theory, removal of uninvolved nodes will not improve the 
prognosis. As a result CLND, which is accompanied by considerable morbidity and costs, seems an 
unnecessary operation in approximately 80 % of SN-positive patients. Therefore, a tool for accurate 
preoperative prediction of NSN involvement is desirable, especially to identify a subgroup of patients 
with such low risk for NSN positivity that CLND can be safely avoided. Many studies have investigated 
clinical and histological factors that predict NSN positivity.9-21 Recently, Murali et al. proposed a new 
scoring system for stratification of risk of NSN positivity which they termed the non-sentinel node 
risk score (N-SNORE).21 The aims of the present study were to identify factors associated with NSN 
positivity in a cohort of Dutch patients and to independently assess the validity of the proposed 
N-SNORE. 
Methods
All patients (n = 130) undergoing CLND after a positive SLNB at the Division of Surgical Oncology of the 
University Medical Center Groningen between 1995 and 2010 were included in this study. 
 To enable SLNB, lymphoscintigraphy with 99mTc nanocolloid was performed the day before 
surgery and patent blue was injected 15-20 minutes before the procedure. All basins identified by 
lymphoscintigraphy were explored surgically and all nodes that were hot and / or blue were removed.22 
 Histopathologic analysis of the SNs consisted of blocking in paraffin and cutting 4 µm thick 
sections at 4 different levels with 250 µm between each level. Sections at each level were stained with 
hematoxylin and eosin and immunohistochemically for S100 and Melan-A. If metastatic melanoma 
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was identified by histopathology or immunohistochemistry, the SLNB was considered positive and 
CLND was performed. For NSNs, histopathological analysis was performed on hematoxylin and eosin 
stained sections of cross-sectioned lymph nodes, and additional immunohistochemistry was not 
performed routinely. 
 Details of the patients, their primary tumors, SLNB, and CLND were prospectively collected in 
a database. The recorded parameters included: age, sex, histologic subtype of primary melanoma, 
Breslow thickness, Clark level of invasion, ulceration, mitotic rate, lymphovascular invasion, satellites, 
regression, number of harvested SNs, number and proportion of involved SNs, extranodal spread 
of tumor, maximum size of largest melanoma deposit in lymph node, and whether metastasis was 
detected by hematoxylin and eosin staining alone or by additional immunohistochemistry.
Statistics 
Missing data were imputed (multiple imputation23) using a model with all factors. For the multiple 
imputation, we generated 5 iterations and combined the estimates and standard errors using Rubin’s 
Rules (micombine in STATA). Prior to running the model we checked whether the data was missing at 
random. We used multiple imputation by chained equations which assumes a multivariate distribution 
exists without specifying its form. In STATA the ICE module was used to perform the multiple 
imputation. A model was built with all missing variables (as shown in Table 1) and outcome. Univariate 
and multivariable binary logistic regression analysis was used to identify independent predictors for 
NSN positivity. A full model including all variables that were deemed important for the outcome was 
built. Since Murali et al demonstrated a significant association with some of the variables, we included 
these variables in the model. A significance level of 5% was used to identify statistically significant 
results. 
 The N-SNORE as described by Murali et al. is a weighted score with a maximum sum of 11 points 
based on the following characteristics: sex (female=0, male=1), regression in primary melanoma 
(absent=0, present=2), proportion of harvested SNs containing metastatic melanoma (≤50%=0, 
>50%=2), perinodal lymphatic invasion in SN (absent=0, present=3), and maximum size of largest tumor 
deposit in the SN (≤0.5 mm=0, 0.51 to 2.00 mm=1, 2.01 to 10.00 mm=2, >10.00 mm=3). The authors 
created 5 risk groups based on the N-SNORE, which stratified the incidence of NSN positivity; very low 
(0%), low (5-10%), intermediate (15-20%), high (40-50%), and very high (70-80%). 21 Assessment of the 
proposed N-SNORE was done by chi-square testing. As the variable perinodal lymphatic invasion (3 of 
11 points), defined as the presence of melanoma cells in lymphatic vascular channels in tissues beyond 
the capsule of the SN24, was not recorded in the patients in the present study, the score was adjusted 
by rearranging the scores for the risk groups and subtracting 3 points from the total.
For the analyses STATA/SE 10.0 version was used (ICE, MIM, MICOMBINE and LOGISTIC).
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Table 1. Clinicopathologic characteristics of 130 sentinel node positive patients and the association 
with non-sentinel node positivity
Characteristic 

























































































































































Number of SN 1
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Abbreviations: SNs, sentinel nodes; H&E, hematoxylin and eosin. 
P-values <0.05 printed in bold.
Median values and range of continuous variables: age 52.1 (20.5-81.0), Breslow 3.0 (1.1-13), mitotic rate 4  (0-20),
number of SN 2 (1-3), number of positive SNs 2 (1-3), size of largest metastasis 1.3 (0-17). 
38
Patient selection for completion lymph node dissection
Results
A total of 130 SN-positive patients [75 males (58%) and 55 females (42%): median age 51.5 (range 5 to 
88) years] underwent CLND. The clinicopathologic characteristics of the patient cohort are presented 
in Table 1. The patients had one (68%) or more (32%) positive SNs. There were 57 axillary (44%), 55 
groin (42%), 16 neck (12%), and 2 popliteal CLNDs. CLND was positive for metastatic melanoma in 30 
patients (23%). Seventeen patients (57%) showed involvement of a single NSN, whereas 13 patients 
(43%) had more than one NSN involved (range 2 to 12). 
Table 2. Univariate and multivariable logistic regression of factors predictive of non-sentinel node positivity
Multivariable analysis 





































Number of positive SN 1
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P-values <0.05 printed in bold. 
Variables found to be associated with non-sentinel node positivity by Murali et al. were 
included in the multivariable model.
Factors associated with positive NSNs in CLND
Factors that were significantly associated with a positive NSN in univariate analysis were histologic 
subtype of the primary melanoma (p=0.03), the presence of regression (p=0.01), and larger size of 
the largest deposit in the SN (p=0.008) (Table 1). As shown in Table 2, presence of regression was 
associated with a positive NSN in multivariable logistic regression (OR 6.3; 95%CI 1.1-36.1; p=0.04). 
Other variables proposed in the N-SNORE were not associated with outcome in the multivariable 
analysis: sex (OR 1.1; 95%CI 0.3-3.5; p=0.9), the proportion of harvested SNs (OR 0.7; 95%CI 0.2-2.6; 
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p=0.6) and size of the metastasis (OR 0.9; 95%CI 0.2-3.8, 3.5; 95%CI 0.7-16.4, 19.6; 95%CI 0.4-1044 for 
0.51-2.00, 2.01-10.0 and >10.0, respectively. Using bootstrap as standard error type, regression was 
not significantly associated with positive NSNs in the CLND (OR 6.3; 95%CI 0.9-44.4; p=0.06).
Table 3. Predictive value of original N-SNORE and modified N-SNORE

















V ery low 0 2.6 0 <0.001 0 7.9 5.9 0.003
Low 1 – 3 40.7 6.4 1 – 2 25.5 13.3
Intermediate 4 – 5 42.0 16.3 3 – 4 39.4 21.1
High 6 – 7 11.7 44.4 5 – 6 23.5 34.6
Very high ≥8 2.9 77.8 7 – 8  3.7 75.0
*      Melanoma Institute Australia.
**    Dutch data University Medical Center Groningen: score adjusted after subtracting points for perinodal  
      lymphatic invasion; max score 8 points.
N-SNORE components: sex (female=0, male=1), regression in primary melanoma (absent=0, present=2), 
proportion of harvested SNs containing metastatic melanoma (≤50%=0, >50%=2), perinodal lymphatic invasion 
in SN (absent=0, present=3), and maximum size of largest tumor in SN (≤0.5 mm=0, 0.51 to 2.00 mm=1, 2.01 to 
10.00 mm=2, >10.00 mm=3); max score 11 points.
N-SNORE
In the present cohort, 7.8%, 46.6%, 35.9%, and 9.7% of patients were in the very low, low, intermediate, 
and high risk N-SNORE categories, respectively. No patients were classified in the very high risk 
category because no points were scored for perinodal lymphatic invasion. The NSN positivity rates 
for these risk groups were 5.9%, 19.8%, 24.5%, and 47.6%, respectively (p=0.04). When the N-SNORE 
system was adjusted for the lack of perinodal lymphatic invasion, there was better stratification of 
NSN positivity in our cohort (p=0.003), with 5.9% NSN positivity in the very low risk category and 75% 
NSN positivity in the very high risk category (Table 3). The measures of prediction accuracy showed a 
reasonable model fit (R2 0.21, linktest p=0.33 and percentage correctly classified 83.6%).
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Discussion
Currently, CLND is recommended for all patients with a positive SN25, although only around 20% of 
these patients will have metastatic melanoma in their NSNs. This retrospective study found that the 
previously proposed N-SNORE (after modification due to missing data on one parameter of N-SNORE, 
i.e. perinodal lymphatic invasion) was a statistically significant predictive model to stratify risk for NSN 
positivity. 
Factors associated with NSN positivity
The rate of NSN positivity in this study was 23%, which is within the range of 8-33% reported in 
literature.9, 10 
 The most frequently cited factors associated with NSN positivity in the literature are thickness 
of primary tumor9-11, 13-15, 18, size of largest SN metastasis10, 11, 13-20, number of positive SN12, 14, 18, 19, and 
perinodal lymphatic invasion10, 16, 21. In this study, we found size of largest metastasis in SLNB to be a 
predictor in univariate analysis (p=0.008). Histologic subtype of primary tumor was predictive of NSN 
positivity in univariate analysis (lower risk for nodular type), a factor that, to our knowledge, has not 
been described previously as a significant predictor of NSN positivity. Regression in the primary tumor 
was a predictor of NSN positivity in both univariate (p=0.01) and multivariable analysis (p=0.04). 
Previous studies that found regression to be a predictor of NSN positivity hypothesized that this could 
be due to an underestimate of primary tumor thickness and other features of aggressiveness (such as 
mitotic rate) in regressed melanoma.10, 11, 21
 Notable factors that were not predictive in our study were Breslow thickness of the primary 
tumor and number of positive SNs. Furthermore, the proportion of affected nodes / total nodes in 
SLNB was not statistically significantly associated with NSN positivity, in contrast to the findings of 
Murali et al.21
N-SNORE 
The N-SNORE model recently proposed by Murali et al. stratified risk for NSN positivity in a study of 
309 SN-positive patients (p<0.001).21 After modifying the score to correct for the missing variable 
perinodal lymphatic invasion in our dataset, we found a significant predictive value for the N-SNORE in 
our Dutch population of 130 SN-positive patients as well (p=0.003) (Table 3). 
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 Comparison of the N-SNORE in both patient cohorts (Table 3) shows increasing NSN positivity 
rates over the increasing risk categories. The percentage of patients classified in the very low risk 
category was higher in the present study. However, the lower risk groups (very low and low) were 
associated with a higher rate of NSN positivity (5.9% and 13.3%, respectively). Therefore, in the 
study of Murali et al the N-SNORE provides better grounds for CLND omission. Addition of perinodal 
lymphatic invasion (if available) is likely to improve stratification of the N-SNORE, especially given the 
strength of the association of this parameter with NSN positivity in Murali et al’s study. Therefore, 
the absence of perinodal lymphatic invasion data in our cohort prevents conclusive validation of the 
N-SNORE model. 
 Although a predictive score like the N-SNORE provides useful prognostic information for both 
physicians and patients, the use of a predictive score as an indicator for CLND avoidance should be 
validated before it can be recommended for routine clinical application. Moreover, the current second 
Multicenter Selective Lymphadenectomy Trial (MSLT-II) should demonstrate whether CLND following 
removal of a positive SN improves outcome compared to clinical and ultrasound monitoring of regional 
node fields with therapeutic lymph node dissection only in cases with manifest nodal metastasis.26
 In conclusion, this retrospective study found regression in the primary melanoma to be an 
independent predictor of a higher risk for NSN positivity. Despite missing the variable perinodal 
lymphatic invasion, useful stratification of the risk of NSN positivity was achieved using the recently 
proposed N-SNORE. For final validation, the scoring system needs to be tested in other large, 
independent datasets, ideally containing details of perinodal lymphatic invasion. 
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Serum S-100B levels are associated with non-sentinel node 
positivity in 68 sentinel node-positive melanoma patients
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ABSTRACT
Background. Completion lymph node dissection (CLND) in sentinel node (SN)-positive melanoma 
patients leads to substantial morbidity and costs, while only about 1 out of 5 patients have a metastasis 
in non-sentinel nodes (NSNs). The aim of the present study was to investigate if biomarkers Lactate 
Dehydrogenase (LDH) and S-100B in SN-positive patients are associated with NSN positivity and thus 
might identify patients in whom CLND could be omitted.
Methods. All SN-positive patients who underwent CLND at a single institution between 2004 and 
mid-2012 were analyzed. Serum LDH and S-100B values measured the day before CLND were tested 
for their association with NSN-positivity. Both the reference cutoff of our institution and an optimal 
cutoff determined by receiver operating characteristic analysis were tested for their association with 
NSN positivity.
Results. A positive NSN was found in 16 of the 68 patients (23.5%) undergoing CLND. Univariate 
analysis revealed Breslow thickness (p=0.04), number of positive SNs (p=0.02), proportion of involved 
SNs (p=0.04), size of largest metastasis in SLNB (p=0.009), and S-100B value (p=0.001) to be associated 
with NSN positivity. LDH level was not significantly associated with NSN positivity (p=0.11). S-100B 
with an obtained optimal cutoff of 0.07 µg/l was a significant independent predictor for NSN positivity 
in multivariable analysis (OR 8.88; p=0.006).
Conclusions. The results of this study show that S-100B with a cutoff within the reference interval 





The most important predictors of prognosis in melanoma patients are tumor thickness according to 
Breslow, presence of ulceration, and mitotic rate of the primary tumor.1, 2 In addition to these primary 
melanoma characteristics, the sentinel node (SN) status determined by sentinel lymph node biopsy 
(SLNB) is of great importance for prognosis.3 SLNB is therefore recommended by the American Society 
of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline, especially in 
intermediate-thickness melanomas (1-4 mm Breslow thickness).4 The fourth interim analysis of the 
first Multicenter Selective Lymphadenectomy Trial (MSLT I) reveals that SLNB followed by immediate 
completion lymph node dissection (CLND) for occult nodal metastasis might lead to improved 
melanoma specific survival.5, 6 
 Generally, when CLND follows a positive SN, one or more positive non-sentinel nodes (NSNs) 
are found in 8-33% of patients.3, 7, 8 In other words, roughly about 4 out of 5 patients will not have 
affected regional nodes, apart from the positive SN. This subgroup of SN-positive patients will not 
improve their outcome through CLND. For these patients a CLND, causing morbidity (wound infections, 
lymph edema, and impaired function) and economic burden, should be avoided.9, 10 The possibility of 
selecting a subgroup of patients with a low risk for NSN positivity could be a key element for omitting 
an unnecessary CLND safely.
 Various parameters have been investigated to select patients who could be treated safely without 
performing a CLND. Association of clinicopathologic factors with NSN positivity, like Breslow thickness7, 8, 
maximum size of metastasis in SN8, 11-14, number of positive nodes in SLNB11, and perinodal lymphatic 
invasion8, 13 have been described in literature. However, those parameters lack predictive strength to 
stratify risk for NSN positivity and so risk scores combining these parameters are suggested7, 13. 
The predictive value of biomarkers has not been investigated for the selection of SN-positive patients 
in whom CLND could be omitted. Serum biomarkers could be stronger predictors of NSN positivity or 
complement suggested risk scores.
 For melanoma, two biomarkers have been extensively studied: Lactate Dehydrogenase (LDH) 
and S-100B.15 The melanoma associated molecule S-100B was found to be a tumor marker in stage III 
and IV disease.16, 17 Elevated levels of serum S-100B were found to be associated with increased risk for 
recurrence and decreased survival in melanoma patients presenting with palpable nodal metastases.18 
The aim of the present study was to investigate if serum levels of LDH and S-100B in SN-positive 
patients could be associated with NSN positivity and thus might identify patients in whom CLND could 
safely be omitted. 
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Methods
From 2004 to mid-2012, all cutaneous melanoma patients with tumor-positive sentinel lymph nodes 
eligible for CLND were prospectively entered in this study. Sentinel lymph node biopsy was only 
performed in patients presenting with a primary melanoma >1 mm Breslow thickness (except for one 
patient who had opted for SLNB with a melanoma of 0.8 mm thickness, presence of ulceration, and 
mitotic rate >1 mm2) without clinically manifest lymph node metastases. 
 The study cohort consisted of patients who earlier underwent wide local excision and SLNB at 
the University Medical Center Groningen (UMCG, a tertiary referral center for melanoma patients) 
as well as patients who were referred to this institution. In case of referral, histopathologic revision 
of the primary tumor and the harvested sentinel lymph nodes was performed at the UMCG before 
scheduling CLND.
 Histopathologic processing of the SNs consisted of blocking in paraffin and cutting of 4 µm sections 
at 4 different levels for routine hematoxylin and eosin staining with additional immunohistochemistry 
for S-100B and Melan-A. If metastatic melanoma was found during this procedure the SLNB was 
considered positive and CLND was performed. For NSNs, histopathologic analysis was done by cross-
section of each lymph node with subsequent hematoxylin and eosin staining without additional 
immunohistochemistry. 
 Characteristics of the patients, the primary tumors, SLNB, and CLND were collected in a database. 
The recorded parameters included: age, sex, histologic type, tumor thickness according to Breslow, 
Clark level, ulceration, mitotic rate, lymphovascular invasion, regression, total number of harvested 
SNs, number of involved SNs, proportion involved SN, size of the largest metastasis in SN, extranodal 
growth pattern, and whether metastasis was detected by hematoxylin and eosin staining alone or by 
additional immunohistochemistry. LDH and S-100B values were measured the day prior to CLND.
Tumor marker assay and reference cutoff
LDH was analyzed routinely by means of Roche Modular (Hitachi) with an enzymatic activity 
measurement; normal values of LDH were considered to be below the reference cutoff of 250 U/l.
 S-100B levels were calculated on the basis of a calibration curve and checked against internal 
standards with a known concentration of S-100B. The reference values for the S-100B assay (Liaison 
Sangtec 100) were established by analysis of S-100B values of 120 healthy individuals according to the 




Characteristics of the patient (age and sex), primary melanoma (histologic type, Breslow thickness, 
Clark level, ulceration, mitotic rate, lymphovascular invasion, and regression), and harvested SNs 
(total number of nodes, number of involved nodes, proportion involved SN, size of the largest nodal 
metastasis, extranodal growth pattern, and detection by hematoxylin and eosin staining only) were 
analyzed for their association with NSN positivity using Fischer’s exact test or the Chi squared test for 
categorical variables and the Mann-Whitney U test for continuous variables. 
 First, the association of continuous data on LDH and S-100B with NSN positivity was studied 
using the Mann-Whitney U test. When p<0.05 for the continuous data, association with NSN positivity 
was tested for the reference cutoff (based on the reference group) and an ‘optimal cutoff point’ 
determined by a receiver operating characteristic (ROC) curve. The optimal cutoff was defined as 
the value showing the highest sum of sensitivity and specificity in the ROC curve. All characteristics 
associated with NSN positivity on a 10% significance level were entered in a multivariable model. 
Subsequently, logistic regression analysis was performed, using a p-value <0.05 to identify significant 
independent predictors. Both continuous and quantitative discrete characteristics were treated as 
quantitative variables in both univariate and multivariable analyses, except for LDH and S-100B levels 
which were categorized for multivariable analysis. Finally, Mann-Whitney U test and Kruskal-Wallis 
test were used to compare serum S-100B levels in the melanoma patients with S-100B levels in 120 
healthy individuals who responded to leaflets in our hospital asking for volunteers. The serum of these 
volunteers was also used to determine the reference cutoff point.
Results
A total of 68 SN-positive patients, consisting of 29 females (42.6%) and 39 males (57.4) with a median 
age of 53 (range 24-89) years, were studied. In 18 of these patients (26.5%) more than one SN 
contained a micrometastasis. 
 Positive NSNs were found in 16 of the 68 patients (23.5%) undergoing CLND. Of these 16 patients, 
6 (37.5%) showed involvement of a single NSN, whereas 10 patients (62.5%) had more than one NSN 
involved. Fifty-two patients (76.5%) had no metastases found in the NSNs. 
Factors associated with positive NSNs in CLND
Univariate analysis revealed the following characteristics to be associated with NSN positivity: Breslow 
thickness (p=0.04), number of positive SNs (p=0.02), proportion of involved SNs (p=0.04), and size 
of largest metastasis in SLNB (p=0.009). S-100B analyzed as continuous variable was associated with 
NSN positivity (p=0.001). LDH as continuous variable did not show a significant association with NSN 
positivity in univariate analysis (p=0.11) and was therefore not further analyzed. (Table 1)
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Association of S-100B with NSN positivity using the reference cutoff
According to the reference cutoff 0.15 µg/l, serum S-100B values were elevated in 5 patients (7.4%). 
This cutoff showed low sensitivity of 31% and high specificity of 100% for NSN positivity (all patients 
with S-100B above cutoff point were NSN positive). In univariate analysis the reference cutoff showed 
significant association with NSN positivity (p=0.001). The percentage of NSN positivity in patients with 
marker values below this cutoff point was 17.5% (false negative rate 69%). (Table 1)
Association of S-100B with NSN positivity using the optimal cutoff
ROC curve analysis of preoperative S-100B values predicting NSN positivity showed an area under the 
curve of 0.77 (Figure 1). S-100B had an optimal cutoff point of 0.07 µg/l. The obtained optimal S-100B 
cutoff showed a more useful association with NSN positivity (sensitivity 75%, specificity 77%; p<0.001) 
than the reference cutoff point (sensitivity 31%, specificity 100%; p=0.001). In multivariable analysis, 
S-100B with the optimal cutoff was a significant independent predictor for NSN positivity (OR 8.88; 
p=0.006). The percentage of NSN positivity in patients with marker values below the cutoff point was 
9.1% for the optimal S-100B cutoff (false negative rate 25%). (Table 1) 
                              Figure 1.  ROC curve of S-100B predicting NSN status
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Table 1. Univariate and multivariable analysis of preoperative characteristics of 68 SN-positive patients 
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Breslow thickness (mm)                 
  Continuous (median, range) 2.9 0.8-11.0 0.04 1.04 (0.71-1.52) 0.86
  T2: 1.01-2.00
  T3: 2.01-4.00
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  Quantitative (median, range) 2 1-6 0.51
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Number of positive SN      
  Quantitative (median, range)  1 1-4 0.02 1.24 (0.45-3.42) 0.68
  1
  2
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Table 1 Continued. Univariate and multivariable analysis of preoperative characteristics of 68 SN-positive patients 
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Preoperative LDH (U/l)                
  Continuous (median, range) 178 110-389 0.11













  Continuous (median, range) 0.06 0.02-1.65 0.001
  S-100B Reference cutoff
  ≤0.15
  >0.15

























Continuous characteristics were tested using Mann-Whitney U test, quantitative discrete characteristics were 
tested using logistic regression analysis. Categorical characteristics were tested with Chi squared test.
Entered in multivariable mode: Breslow thickness, number of positive SN, size of largest SN metastasis, S-100B 
optimal cutoff.
All p-values <0.05 are printed in bold. 
*  Optimal S-100B cutoff based on receiver operating characteristic curve.
** N/A: not addressed due to 100% NSN positivity for S-100B levels >0.15 µg/l.




S-100B levels in SN-positive melanoma patients compared to healthy individuals 
The serum S-100B levels measured in 120 healthy individuals (median 0.07; range 0.01-0.59) did not 
significantly differ from the serum levels in 68 SN-positive patients (median 0.06; range 0.02-1.65; 
p=0.44) (Figure 2). When the melanoma patients were categorized into a NSN negative and a NSN 
positive group significant differences in S-100B levels were found. For 120 healthy individuals, 52 NSN 
negative melanoma patients, and 16 positive melanoma patients, the median S-100B levels were 0.07 
(range 0.01-0.59), 0.05 (range 0.02-0.14), and 0.09 (range 0.02-1.65), respectively (p=0.001). NSN 
negative patients showed lower S-100B levels (p=0.03), and NSN positive patients show higher levels 
compared to healthy individuals (p=0.008). (Figure 3)
Figure 3. Comparison of S-100B levels in healthy individuals and SN positive 
melanoma patients according to NSN status
Figure 2. Comparison of S-100B levels in healthy individuals and SN positive 
melanoma patients
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Discussion
Based on a systematic review, the American Society of Clinical Oncology and the Society of Surgical 
Oncology recently officially stressed the importance of SLNB performance for accurate melanoma 
staging, especially for intermediate-thickness melanomas (1-4 mm Breslow thickness). In case of a 
positive SN, performance of CLND is recommended in their guideline until the risks of CLND omission 
are fully explored by the pending second Multicenter Selective Lymphadenectomy Trial (MSLT-II).4, 20. 
 In anticipation of MSLT-II results, various studies were performed to identify clinicopathologic 
factors that predict of risk for NSN positivity to enable future patient selection for CLND omission. 
In particular, the size of the sentinel node metastasis seemed a good predictor for this purpose. 
Especially the investigators of the Daniel den Hoed Cancer Center in Rotterdam have performed 
extensive research on this and developed the so called ‘Rotterdam Criteria’ for SN tumor load. In 
their studies, a SN metastasis smaller than 0.1 mm showed to be predictive for low NSN positivity risk 
and was even suggested to be considered SN negative11, 21 Although the impact on prognosis of CLND 
omission in patients with minimal SN tumor burden is currently being explored by the EORTC MINITUB 
registration study22, more recently discussion about its value rose because underestimation of the 
deposit size could possibly prevent safe use of this factor for CLND avoidance.14, 23. While this debate 
triggers further investigation on histopathologic predictors of NSN positivity, no studies concerning the 
use of biomarkers to improve patient selection for CLND avoidance are being published.
 This study is, to our knowledge, the first to investigate the association of LDH and S-100B levels 
with NSN positivity in SN-positive melanoma patients. For AJCC stage I and II, various studies have 
concluded that neither serum S-100B nor LDH were capable of predicting the SN status because of low 
sensitivity of these markers with the used cutoff points.24-26 However, all these studies only used cutoff 
points based on a group of apparently healthy individuals. 
 Of the 68 SN-positive melanoma patients who underwent CLND, 16 patients (23.5%) showed 
metastatic involvement of NSNs. Using the serum marker S-100B with a cutoff below the 0.15 µg/l 
reference cutoff of our institution enabled useful stratification of risk for NSN positivity. The cutoff 
of 0.07 µg/l, obtained by ROC analysis, was an independent predictor for NSN positivity (OR 8.88; 
p=0.006). The S-100B marker showed a 9.1% NSN positivity in patients with values below the 0.07 
µg/l cutoff versus 50.0% for patients with values above this cutoff. S-100B using the standard 0.15 µg/l 
reference cutoff, although significantly associated, was not useful to stratify risk for NSN positivity due 
to low sensitivity. Moreover, LDH as continuous variable was not associated with NSN positivity.
 Other variables associated with NSN positivity in univariate analysis were Breslow thickness, 
number of positive nodes in SLNB, and size of largest metastasis in SN. Although not significant on 
multivariable analysis, these three factors reflect the most reported predictors for NSN positivity in 
current literature.7, 8, 11-13, 21, 27-34 These histopathologic parameters, especially when combined with 




 In current clinical practice, S-100B levels above the reference cutoff (0.15 µg/l in our institution) 
are used as an indicator for tumor load in stage III and IV melanoma.16-18 Predicting NSN positivity with 
the reference cutoff of 0.15 µg/l however resulted in a low sensitivity. This was significantly improved 
when using the cutoff of 0.07 µg/l, making S-100B a useful predictor for NSN positivity. A predictive 
capacity for S-100B with a cutoff point within the reference interval might feel counterintuitive, as 
S-100B values within the reference range of healthy individuals could hardly reflect melanoma tumor 
load. However, biochemical studies show that the S-100B protein inhibits tumor suppression by p53 
and apoptosis in melanoma, thereby probably contributing to disease progression.35, 36 Following this 
theory, it could be hypothesized that with increasing inherent S-100B levels metastatic tendency of 
melanoma cells enhances, increasing the risk for NSN positivity. In this situation, patients with higher, 
although within the ‘normal’ range, serum S-100B originating from e.g. the neurological system would 
show more aggressive melanoma tumor biology and higher risk for NSN involvement. This mechanism, 
with the S-100B protein as driver rather than passive marker, might explain the finding of a useful 
predictive cutoff below the reference cutoff of 0.15 µg/l in the present study. 
 Comparison of S-100B levels in healthy individuals and melanoma patients in the present 
study seem to support the latter theory. Serum S-100B levels in healthy individuals and SN-positive 
melanoma patients were found to be similar (Figure 2). When categorized for NSN status, NSN negative 
patients showed lower S-100B levels (p=0.03), and NSN positive patients show higher levels compared 
to healthy individuals (p=0.008) (Figure 3). 
 Compared to other described predictors of NSN positivity, S-100B with cutoff 0.07 µg/l showed 
a high OR and relative good sensitivity (univariate OR 8.88; sensitivity 75%).7, 8, 11-13. To enable clinical 
applicability, the accurateness of NSN positivity risk stratification should be further increased by 
combining the S-100B value with other clinicopathologic predictors in a risk score.
Prediction of NSN positivity by integrating the preoperative S-100B level into a NSN risk score could 
prevent the performance of unnecessary CLND, entailing costs and a high risk for complications, in a 
substantial number of patients. In this study, selection using the cutoff level of 0.07 µg/l would mark 
64.7% of patients as low risk based on S-100B level alone (Table 1), although combining S-100B with 
other predictors will lower this percentage. 
 Before using the biomarker S-100B for omitting CLND, its predictive capacity and sensitivity 
should be validated in large independent patient cohorts. Moreover, the current MSLT-II trial should 
first demonstrate whether CLND following removal of a positive SN improves outcome compared to 
clinical and ultrasound monitoring of regional node fields with therapeutic lymph node dissection only 
in cases with manifest nodal metastasis.20
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 In summary, this study with a limited number of patients shows that S-100B levels of SN-positive 
melanoma patients are independently associated with NSN positivity. Using a S-100B cutoff point 
within the reference interval could further improve selection of SN positive patients in whom CLND 
could safely be omitted by integration of this biomarker in NSN risk scores. However, the findings of 
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ABSTRACT
Background. The purpose, frequency and content of follow-up (FU) visits have been widely debated 
for all common malignancies, including melanoma. The aim of this study was to gain insight into Dutch 
medical specialists’ opinions on melanoma FU and to assess their views on sentinel lymph node biopsy 
(SLNB).
Methods. All members of the Dutch Society of Surgical Oncology and the Dutch Society of Dermatology 
and Venereology were invited to complete a web-based questionnaire, consisting of 25 questions 
addressing the following topics: 1) respondent characteristics, 2) knowledge of national melanoma 
guideline, 3) opinions on melanoma FU, and 4) view on the significance of SLNB.
Results. A total of 378 respondents (response=37%) started the survey, including 173 surgeons (46%) 
and 205 dermatologists (54%). With the exception of one, respondents (99.7%) reported that they 
knew the content of the Dutch national melanoma guideline. Of these, 97% agreed that the purpose 
of FU was detection of local recurrence and 92% agreed that it was detection of a second primary. 
Concerning frequency of FU in the first 10 years after diagnosis, 42% preferred a less frequent FU than 
indicated by the current guideline, while 4% preferred more frequent FU. Dermatologist and surgeon 
should be involved in FU according to 77% and 37% of respondents, respectively. 
Conclusion. The majority of Dutch medical specialists consider melanoma FU to be primarily an 
instrument to detect recurrences and secondary primaries. The frequency of FU, as prescribed by the 




As the number of patients with cancer continues to increase, medical specialists are striving to 
optimize treatment and follow-up (FU). Among various types of cancer, melanoma has one of the 
fastest increasing incidence rates in the western world. In the Netherlands the incidence of melanoma 
doubled in the past two decades, from 11.3 per 100 000 in 1989 to 26.3 per 100 000 in 2009.1 In the 
United States, it is estimated that over 70 000 people will be diagnosed with melanoma in 2012.2 
 The purpose, frequency, and content of follow-up visits have been widely debated for all common 
malignancies, including melanoma. To date, high frequency FU, including up to four hospital visits 
per year, is recommended by national guidelines in countries with the highest melanoma incidence.3 
While medical specialists’ opinions on the purpose and effectiveness of FU have been investigated for 
other malignancies, such as colon and breast cancer4, 5, views on FU for melanoma remain unknown. 
 The aim of this study was to examine Dutch medical specialists’ knowledge of the national 
melanoma guideline and to gain insight into their opinions on the purpose, frequency, and organization 
of FU in melanoma patients through a web-based survey. Additionally, respondents’ views on sentinel 
lymph node biopsy (SLNB) were assessed. 
 
Methods
Procedure and respondents 
An e-mail explaining the goal of the study, an invitation to participate, and a hyperlink to the 
questionnaire was sent by the investigators to all members of the Dutch Society of Surgical Oncology 
(n=435 surgeons) and the Dutch Society of Dermatology and Venereology (n=600 dermatologists) in 
May 2010. A reminder email was sent after four weeks. All completed questionnaires were processed 
anonymously.
Instrument
A 25-question, web-based questionnaire was created using www.surveymonkey.com. In the present 
article we address the questions dealing with the following four subjects: 1) characteristics of 
respondent (five questions), 2) knowledge and adherence to the current Dutch melanoma guideline 
(three questions), 3) opinions on FU, including purpose, frequency and duration, and organization 
(seven questions, with accompanying subquestions), and 4) respondents’ opinions on the guideline’s 
recommendations for SLNB (three questions).
 Questions on subjects one through three were derived from the questionnaire on medical 
specialists’ attitude on FU in breast cancer patients from van Hezewijk et al. and modified to fit 
incidence and disease characteristics of malignant cutaneous melanoma.4
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Current national guideline
The current Dutch melanoma skin cancer guideline, published in 2005, recommends a single FU visit 
for melanomas thinner than 1 mm according to Breslow.6 For melanomas between 1 mm and 2 mm, 
the FU schedule after diagnosis consist of four visits during the first year, three visits during the second 
year, and two visits per annum up to the fifth year. Patients with a melanoma thicker than 2 mm are 
additionally evaluated annually during years 6 to 10 after diagnosis. 
 Regarding the SLNB, the 2005 Dutch melanoma guideline states that this procedure is not part of 
standard diagnostics of cutaneous melanoma and that the procedure has to be reserved for patients 
who want to be optimally informed about stage of their disease. 
Statistical analysis 
Frequencies and percentages were calculated. Differences between specialists with a surgical and 
a dermatological background were analyzed using chi-square tests with a significance level of 5%. 
Figures were created using GraphPad Prism 5.00. Statistical analysis was performed using the SPSS 
software package (SPSS 18.0, Chicago, Illinois, USA). 
Results
Respondents’ characteristics
A total of 378 respondents (response rate = 37%) started the survey, including 173 surgical (46%) and 
205 dermatological (54%) medical specialists (Table 1). Of these, 352 respondents (93%) completed 
the questionnaire. Table 1 shows that respondents were from all types of hospitals with almost half 
working in a district training hospital. Twenty-eight percent of respondents (39% of surgeons and 19% 
of dermatologists, p<0.001) indicated that fewer than 30 new melanoma patients were diagnosed 
and treated in their hospital annually. Eighty-nine percent of medical specialists themselves (88% of 
surgeons and 90% of dermatologists, p=0.559) treated fewer than 30 new melanoma patients annually. 
Current guideline
All but one of the medical specialists (99.7%) indicated they knew the content of the national melanoma 
skin cancer guideline. Of these, 36% responded they always followed the guideline’s recommendations 
while 64% stated they incidentally deviated from it for an appropriate reason (percentages similar for 
surgeons and dermatologists). Forty-two percent reported that the national guideline was integrated 
into local hospital guidelines. The remaining 58% indicated that the national guideline was not 




• Purpose and goals
Ninety-seven percent of respondents (totally) agreed that detection of local recurrences was a goal of 
FU. Percentages of specialists (totally) agreeing on other purposes of FU were: 92% on detection of a 
second primary, 84% on detection of regional or distant metastases, 72% on detection of late effects 
of treatment, and 65% on identifying psychological problems. Fewer than half of respondents (totally) 
agreed that assessing quality of life and recording patient status for research purposes were a purpose 
of FU (48% and 22%, respectively). (Figure 1a) 
Table 1. Characteristics of 378 respondents
Characteristic n %
Discipline
  Surgical oncologist 
  Surgeon
  Surgical resident  
  Dermatologist












  University Hospital
  District training hospital
  District non-training hospital
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 Opinions on the purpose of FU differed significantly between surgeons and dermatologists on 
three items. The percentage of surgeons (totally) agreeing that detection of second primaries and 
detection of regional and distant metastasis were a purpose of FU was lower than that of dermatologists: 
84% versus 97% (p<0.001) and 74% versus 93% (p<0.001), respectively. Fewer dermatologists (totally) 
agreed that research was a purpose of FU than surgeons (18% versus 40%, p<0.001). (Figure 1b) 
 Sixty-six percent of specialists (55% of surgeons and 78% of dermatologists, p<0.001) (totally) 
agreed that early detection of a local recurrence or secondary primary would improve the chance 
for cure. Twenty-four percent thought that a more frequent FU would improve quality of life (14% of 
surgeons and 32% of dermatologists, p<0.001).
Figure 1. (a) Purpose of follow-up; (b) Purpose of follow-up according to Dermatologists and Surgeons
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• Frequency of visits
The current national guideline prescribes a single FU visit after curative treatment of a primary 
melanoma thinner than 1 mm according to Breslow. Of all respondents, 27% totally agreed, 54% 
partially agreed, and 19% disagreed. Ten percent of surgeons disagreed while 38% totally agreed, 
and 27% of dermatologists disagreed while 18% totally agreed (p<0.001). When asked what the 
optimal FU frequency would be according to melanoma stage, compared to the current guideline 
recommendations, a slightly different pattern for stage Ia melanoma emerged: 52% of specialists 
answered they considered a single FU consultation for stage Ia disease to be good, 39% of specialists 
would prefer a more frequent FU schedule, and 4% would prefer less frequent FU (Figure 2a). For 
the more advanced stages of melanoma, only between 1% and 4% of the respondents would prefer 
more frequent FU. Less frequent FU was preferred by 45% of respondents for stage Ib disease, by 
37% for stage IIa disease, by 32% for stage IIb, by 29% for IIc, and by 22% for stage III disease. (Figure 
2a) Generally over the first 10 years after diagnosis, a less frequent FU was preferred by 42% of 
respondents and only 4% indicated they would like more frequent FU. Six percent of respondents 
indicated they would like FU visits to continue beyond the tenth year after diagnosis. (Figure 2b)
Figure 2. (a) Preferred follow-up frequency according to melanoma stage; (b) Preferred follow-up frequency 
according to year after diagnosis
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• Responsibility
When asked which professionals currently perform FU after primary treatment, 56% of the respondents 
(63% of surgeons and 50% of dermatologists) answered a dermatologist as well as a surgeon, 30% (9% 
of surgeons and 47% of dermatologists) answered the dermatologist only, and 14% (26% of surgeons 
and 3% of dermatologists, p<0.001) stated the surgeon only. Five percent stated that a physician 
assistant or nurse practitioner was involved. When asked which professional should always, never, or 
in select cases be involved in the FU of melanoma, 77% (59% of surgeons and 91% of dermatologists, 
p<0.001) answered a dermatologist should always be involved and 37% (50% of surgeons and 25% of 
dermatologists, p<0.001) replied a surgeon should always be involved. Of the respondents, 21% (34% 
of surgeons and 10% of dermatologists, p<0.001) indicated a physician assistant or nurse practitioner 
should always be involved in FU and 5% (6% of surgeons and 3% of dermatologists, p=0.067) 
responded that a general practitioner (GP) should always be involved. In contrast, respondents stated 
some specialists should never be involved in melanoma FU: 43% excluded the GP, 26% the physician 
assistant or nurse practitioner, 2% the surgeon, and 2% the dermatologist. (Figure 3) 
Figure 3. Proposed degree of involvement in follow-up according to Dermatologists and Surgeons
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Sentinel lymph node biopsy 
Overall, 75% of respondents agreed that the standard diagnostics of cutaneous melanoma does not 
include a SLNB and that this procedure should be reserved for patients who want to be optimally 
informed about their prognosis. Sixty-nine percent of surgeons agreed with this versus 80% of 
dermatologists (p=0.012). When asked for which Breslow thickness there is an indication for SLNB, 
2% responded all melanomas regardless of Breslow thickness, 61% answered all melanomas thicker 
than 1 mm, and 37% answered melanomas between 1.0 and 4.0 mm thickness. Forty-three percent 
of surgeons reported performing SLNB in all nodal regions, 49% only in the groin and the axilla, and 
8% stated they never perform SLNB. Five percent of dermatologists stated they performed SLNB in all 
nodal regions, 6% answered they performed SLNB only in the groin and the axilla, and 89% did not 
perform SLNB. 
Discussion
In this study we investigated the opinions of Dutch surgeons and dermatologists treating melanoma 
patients on two ‘hot items’ in melanoma care: melanoma FU and SLNB. The online survey we used 
obtained a response rate of 37%. This is slightly better than rates obtained by other web based surveys 
asking medical specialists to participate4, 5. With the exception of one, respondents (99.7%) knew the 
content of the Dutch national melanoma guideline and one-third stated that they always adhered 
to the guideline’s recommendations. However, two-thirds stated to reported incidental deviations 
from the guideline. Overall, the highest numbers of respondents agreed that detection of recurrences 
and secondary primaries are a purpose of FU. Although two-thirds of respondents believe that early 
detection of recurrent melanoma improves the chance for cure, 42% of respondents believe that the 
frequency of FU, as prescribed by the current guideline, could be reduced. Three-quarters of specialists 
have the opinion that SLNB does not belong to the standard diagnostics of cutaneous melanoma, even 
though it is part of the seventh American Joint Committee on Cancer (AJCC) staging system7. 
Follow-up 
• Purpose and goals
Detection of a local recurrence and a second primary melanoma were considered by the vast majority 
of respondents to be a purpose of FU. This suggests that these two objectives were considered to be 
the most important reasons for routine melanoma FU visits by Dutch medical specialists. Comparable 
percentages of surgeons and dermatologists agreed on the importance of four of the seven FU 
purposes. However, fewer surgeons than dermatologists agreed that detection of second primaries 
and detection of regional and distance metastasis is a purpose of FU. In contrast, fewer dermatologists 
than surgeons reported that research would be a purpose of FU. The cause for these differences in 
focus on FU purpose is not clear. It may reflect that dermatologists more than surgeons habitually 
inspect the whole body to screen for lesions, whereas surgeons may tend to focus on the primary site 
and the regional nodal basin.
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• Frequency of visits
According to 42% of respondents, FU visits in the first 10 years after diagnosis could be scheduled 
less frequently than recommended in the current guideline. Only 4% desired a more frequent 
schedule. Surprisingly, Holterhues et al. showed that a substantial proportion of Dutch melanoma 
patients received more frequent FU than recommended by the present guideline.8 Therefore, better 
adherence to the guideline combined with a less frequent FU schedule could significantly reduce 
overconsumption, increase cost-effectiveness, reduce demand on health care resources, and lower 
patients anxiety levels potentially linked to hospital visits9, 10. 
 It has been found that most recurrences (about three-quarters) are detected by the patient 
rather than by the professional during a FU visit11-13. Also, the frequency of FU visits does not seem 
to affect survival or quality of life14, 15. These two points support a reduction in number of FU visits. 
Thirdly, a recent study showed that the estimated time gain for detection of a recurrence or second 
primary due to the current high frequency FU, compared to a less intensive FU, is very small.16 A less 
frequent FU schedule is proposed in the 2012 draft version of the new Dutch melanoma skin cancer 
guideline. 
• Responsibility
The majority of respondents stated that the dermatologist and/or the surgeon are and should be 
responsible for FU of melanoma patients, either always or in select cases.3 This is conforming to 
most melanoma guidelines. Some studies suggest that GP-led FU is feasible10, 17, 18 However, 43% of 
respondents discouraged involvement of the GP in Dutch melanoma FU. Also, 26% of respondents 
disapproved of the involvement of a physician assistant or nurse practitioner. Thus, dermatologist 
and to a somewhat lesser extent surgeons want to remain responsible for melanoma FU and seem 
not yet ready to hand this task over to the GP or to nurse practitioners and physician assistants. This 
is remarkable because it has been suggested that these latter professionals could well be integrated 
in FU for other malignancies19, 20, thereby reducing medical specialists’ workload and increasing cost-
effectiveness. 
 Responsibility for FU may depend on the stage of disease. For instance, the dermatologist could 
perform FU in stage I and II melanoma patients while a surgical oncologist could be involved in the 
FU of patients having more advanced disease, because of the higher probability of diagnostic imaging 
and operative interventions. It may be that the current shift towards a disease-centered approach in 
larger hospitals in the Netherlands, with close collaboration between surgeons, dermatologists, and 




In this study, 39% of responding surgeons and 19% of dermatologists reported a low number (fewer 
than 30) of new melanoma patients presenting to their hospital annually. The association of hospital 
volume with outcomes of advanced surgical procedures is well-known.21 It could be hypothesized 
that hospitals treating melanoma patients need to see at least 30 new melanoma patients annually 
(entailing roughly six recurrences)14 in order to have enough experience with surgical procedures such 
as SLNB and lymph node dissections. The Dutch collaborative group for cancer specialists (SONCOS)22 
stated in their quality framework of 2011 that, in order to secure high quality care for cancer patients, 
hospitals treating melanoma patients are required to: 1) have a minimum of two surgeons experienced 
in performing SLNB in all nodal basins, 2) perform at least 20 deep groin dissections and 3) treat 20 
patients systemically each year. Smaller hospitals not reaching these numbers of melanoma patients 
should refer to a larger clinic or a melanoma center to optimize outcomes. Following these quality 
requirements, it might be concerning to find that 49% of surgeons reported that they perform SLNB 
only in the groin and axilla. These surgeons should consult a head and neck surgeon for patients with 
a melanoma located in the head and neck region. 
Sentinel lymph node biopsy  
At the time of questionnaire completion, 75% of respondents agreed with the guideline’s 
recommendation that excludes SLNB from the standard diagnostic path for melanoma. Despite its 
incorporation into the AJCC melanoma staging manual in 2002, the Dutch specialists, endorsed by the 
content of the 2005 national guideline, seem to remain predominantly conservative in their opinion 
about the use of SLNB and the prognostic advantage of this procedure. This finding is reflected by 
the results of a recent analysis of 2111 patients from the northern part of the Netherlands with a 
melanoma thicker than 1 mm: fewer than half of these patients underwent SLNB, even in the most 
recent years.23 The fourth interim analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) 
suggest a 7% (78% versus 71%) benefit in 10-year melanoma-specific survival for patients undergoing 
SLNB.24 Faster adjustment of both the Dutch medical specialists’ attitude and the Dutch guideline to 
the SLNB is required if this survival benefit persists in the final MSTL-I analysis.
Limitations
The response rate (37%) in the present study is rather low, although comparable with response 
rates obtained in other web based surveys asking specialists to participate. This may affect the 
representativeness of the sample. Moreover, this study does not include the points of view of medical 
specialists other than surgeons and dermatologists, such as physician assistants, nurse practitioners, 
or GPs. Finally, the survey did not record the rationale respondents had for their point of view. 
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Future perspectives 
A considerable proportion of medical specialists believe the frequency of melanoma FU visits in the 
Netherlands could be reduced. If the results of the current Dutch melanoma follow-up (MELFO) trial25 
confirm the feasibility and safety of reduced and patient-tailored FU schedules, the rising demand on 
health care resources can be decreased by strict compliance with new FU guidelines. Furthermore, 
patient-tailored FU can be accompanied by improvements in patients’ knowledge of melanoma through 
education using instruction videos on self-examination and by the development of cancer survivorship 
plans to increase recurrence detection by patients and reduce their need for FU visits. Therefore, in 
collaboration with the Dutch Cancer Foundation, the University Medical Center Groningen developed 
instruction videos that can be viewed online (http://www.youtube.com/watch?v=P5qKpCjXaLA  and 
http://www.youtube.com/watch?v=dfP995HvBLA).
 Additionally, combined FU by dermatologist and surgical oncologist in a disease-centered (e.g. 
melanoma clinic) approach may further increase quality and cost-effectiveness. The majority of 
respondents stated that FU was and should be performed by both dermatology and surgical oncology. 
Views on these subjects could change considerably among the surveyed population if recent 
breakthroughs in medical treatment of recurrent melanoma (ipilimumab and vemurafenib)26, 27 are 
demonstrated to have a true effect on survival. In that case, early detection with subsequent medical 
treatment for recurrences might improve survival and therefore the frequency and content of FU 
might also stronger influence survival.
 In the present situation, however, a disease-centered approach in high volume centers with less 
frequent FU could increase cost-effectiveness of melanoma care and seems to be supported by at least 
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Therapeutic lymph node dissection in melanoma: different 
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ABSTRACT
Background. The prognostic significance of primary tumor location, especially the worse prognosis 
for melanomas in the scalp and neck region, is well established. However, the prognosis for different 
sites of nodal macrometastasis has never been studied. This study investigated the prognostic value 
of the location of macrometastasis in terms of recurrence and survival rates after therapeutic lymph 
node dissection (TLND).
Methods. All consecutive FDG-PET-staged melanoma patients with palpable and cytologically proven 
lymph node metastases operated at our clinic between 2003 and 2011 were included. Disease-free 
survival (DFS) and disease-specific survival (DSS) were compared for nodal metastases in the groin, 
axilla, and neck regions using multivariable analysis.
Results. A total of 149 patients underwent TLND; with 70 groin (47%), 57 axillary (38%), and 22 
neck (15%) dissections. During a median follow-up of 18 (range 1–98) months, 102 patients (68%) 
developed recurrent disease. Distant recurrence was the first sign of progressive disease in 78%, 76%, 
and 55% of the groin, axilla, and neck groups, respectively (p=0.26). Low involved/total lymph nodes 
(L/N) ratio (p<0.001) and absence of extranodal growth pattern (p=0.05) were independent predictors 
of a longer DFS. For DSS, neck site of nodal metastasis (p=0.02) and low L/N ratio (p<0.001) were 
independent predictors of long survival. The estimated 5-year DSS for the groin, axilla, and neck sites 
was 28%, 34%, and 66%, respectively.
Conclusion. There seems significantly longer DSS after TLND for nodal macrometastases in the neck 
compared to axillary and groin sites, although larger series should confirm this finding.
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Background
The incidence of melanoma continues to increase in the Western world. In the Netherlands, the 
incidence doubled over the past two decades, to 26.3 per 100,000 in 2009 from 11.3 per 100,000 in 
1989.1, 2 Most patients present initially with Stage I or II melanoma.3 Unfortunately, despite defined 
surgical treatment of the primary melanoma with excision margins of 1 or 2 cm, approximately 16–
28% of patients develop recurrent disease. These recurrences occur locally or in-transit in 20–28%, 
distant in 15–50%, but most frequently in regional lymph nodes (26–60%).4 
 When nodal recurrence is detectable clinically (stage IIIB-C), patients may benefit from 
therapeutic lymph node dissection (TLND) with or without adjuvant radiation treatment in terms of 
regional tumor control and survival, resulting in a 5-year survival rate of 29–52%.3, 5-9 Major predictors 
of an unfavourable prognosis are greater Breslow thickness, the presence of ulceration, and a high 
mitotic rate. The Clark level, the location of the primary melanoma, age, and sex are less important 
predictors.3, 10 The prognostic significance of primary melanoma characteristics can not be identified 
for patients with nodal metastasis undergoing TLND.5 For this group of patients, a recent study showed 
that a preoperatively elevated S-100B tumor marker had a negative prognostic value.11 
 The prognostic significance of primary tumor location, especially worse prognosis for melanomas 
in the scalp and neck region, is well established.12, 13 However, the prognostic value of the anatomical 
location of nodal recurrence in stage IIIB-C melanoma has not previously been investigated. Patients 
with nodal metastasis are at high risk for distant metastasis. Therefore, stage III melanoma patients 
with palpable lymph node metastases are staged by whole body FDG-PET and spiral CT at our center 
in the last decade, avoiding unnecessary surgery in the presence of systemic disease in 15.5% of these 
patients.14 
 The aim of the present study was to analyse the site of recurrence, the disease-free survival 
(DFS), and the disease-specific survival (DSS) according to the anatomical location of lymph node 
metastasis (groin, axilla, and neck) in optimally staged patients with melanoma stage IIIB-C. 
Patients and Methods 
All consecutive melanoma patients with palpable and cytologically proven lymph node metastases 
diagnosed at the Division of Surgical Oncology of the University Medical Center Groningen (UMCG), 
the Netherlands, between 2003 and 2011 underwent staging with whole-body FDG-PET and spiral-CT. 
All patients were informed about their stage of disease, type of regional nodal dissection, and potential 
perioperative complications, according to the UMCG standards. Those with distant metastases or with 
more than one affected lymph node basin were excluded from this study. A total of 149 stage IIIB-C 
melanoma patients underwent a therapeutic lymph node dissection. In this group, only 7 patients had 
been staged previously using sentinel lymph node biopsy (SLNB), which was negative in 6 cases. The 
single patient with a positive SLNB refused a proposed completion lymph node dissection (CLND) at 
the time and recurred later in the affected regional lymph node basin. 
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All therapeutic dissections were performed by experienced surgical oncologists. A level I-III axillary 
dissection was performed with resection of the minor pectoral muscle. Groin dissection comprised 
superficial (inguinal) and deep (iliac and obturator) lymph node dissection with sartorius muscle 
transposition.15 Neck dissection included radical removal of lymph nodes in levels I-III, I-V, and II-V, 
including the posterior compartment depending on indication. A subtotal dissection of the parotid 
gland was performed depending on the localization of the lymph node metastasis and the primary site.
 Patients with positive lymph nodes larger than 3 cm, 3 or more positive lymph nodes, and/or 
extranodal growth pattern received adjuvant radiotherapy (45-60 Gy).16, 17 All patients with recurrence 
after TLND were discussed in a multidisciplinary melanoma conference and received what is termed 
a ‘tailored treatment’ i.e. surgery, radiation, and/or systemic treatment according to the current 
standard or experimental treatment protocols. 
Statistical analysis
Characteristics of the patient (sex and age), primary melanoma (Breslow thickness, Clark level, 
ulceration, mitotic rate, and primary site), and lymph node metastasis (interval to metastasis, 
extranodal growth pattern, total number of nodes, number of involved nodes, involved/total 
lymph nodes (L/N) ratio, and size of the largest nodal metastasis) were recorded and analyzed for 
differences between the groin, axillary, and neck groups. Fischer’s exact test or the Chi squared test 
for categorical variables and the Kruskal-Wallis test for continuous variables were used to analyze the 
differences using a significance level of 5%. DFS and DSS were calculated from the date of the TLND. 
Univariate and multivariable Cox Proportional Hazards Analysis were used to assess DFS and DSS for 
different nodal metastasis locations, with an event defined as any recurrence for DFS and death due 
to melanoma for DSS. All factors significant at a 10% significance level in univariate analysis were 
included in a multivariable model along with sex, age, Breslow thickness, and ulceration. Quantitative 
characteristics were entered as continuous variables in univariate and multivariable analysis on DFS 
and DSS. Because of its prognostic significance we used the L/N ratio rather than the number of 
involved nodes for multivariable analysis.18-20 A backward stepwise method was used subsequently to 
identify independent predictors for DFS and DSS on a 5% significance level.
Results
A total of 149 patients underwent TLND. There were 70 groin dissections (47%), 57 axillary dissections 
(38%), and 22 neck dissections (15%). The median age was 58 (range 16-93) years and 64 patients 
(43%) were female.  
 Significant differences in characteristics between the three lymph node basin groups were found 
for sex (p=0.001, with more males in the axilla and neck groups), Clark level (p=0.05, lower in neck 
group), total number of harvested nodes (p=0.04, higher in neck group) and size of largest lymph node 
metastasis on pathological examination (p<0.001, with smaller metastases in the neck group). (Table 1)
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Table 1. Patient characteristics according to location of lymph node metastasis
Variable           No. of patients (%)
Groin Axilla Neck p-value 
Sex 










   Median (range)
  <50
   50-64















  Median (range)
  T1 (<1.00) 
  T2 (1.00-2.00) 
  T3 (2.00-4.00) 
  T4 (>4.00)  





















  II / III























  Absent 












Mitotic rate per mm2

















Interval primary – nodal metastasis (years) a
  Median (range)
  ≤2 years





















Total no of Nodes 
  Median (range) 15 (2-38) 16 (6-43) 24 (3-70) 0.04
Number of involved nodes 
  Median (range) 
  N1 (1)
  N2 (2-3)
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Table 1 continued. Patient characteristics according to location of lymph node metastasis
Variable No. of patients (%)
Groin Axilla Neck p-value 
Ratio of involved / total nodes (%)

















Size of nodal metastasis (cm) 




























  Median (range) 19 (1-93) 16 (1-98) 43 (3-94) 0.05
a  Unknown primary melanoma not included in calculation of interval.
b   According to the 7th melanoma classification of the American Joint Committee on Cancer.
Site of recurrence 
One hundred two patients (68%) developed recurrent disease during follow-up. As shown in Table 2, 
a large proportion of patients in the groin and axilla groups had recurrent disease and presented with 
distant metastases as the first sign of progressive disease (78% and 76%). In the neck group, only 55% 
of patients presented with a distant metastasis as the first site of recurrence (p=0.26). 
Table 2. Site of first recurrence after therapeutic lymph node dissection according to 
location of the lymph node metastasis
Recurrence* No. of patients (%)
Local Locoregional Distant p-value
Groin 2 (4) 10 (18) 42 (78) 0.26
Axilla 4 (11) 5 (13) 28 (76)
Neck 1 (9) 4 (36) 6 (55)
* Patients presenting with both local or locoregional and distant recurrences were classified as distant. 
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Recurrence and survival rates
The follow-up for the entire group was 18 (range 1–98) months with an estimated 5-year DFS of 27% 
(95% CI: 19–34%) and an estimated 5-year DSS of 37% (95% CI: 28–45%). The estimated 5-year DFS 
for the groin, axilla, and neck groups was 12%, 27%, and 49%, respectively (Figure 1a). Variables 
associated with DFS in univariate analysis were presence of ulceration, the location of nodal metastasis, 
extranodal growth pattern, L/N ratio, and the size of the largest nodal metastasis. Neck location of 
the metastasis showed a significantly longer DFS in univariate analysis. (Table 3) The multivariable 
model showed a lower L/N ratio (p<0.001) and absence of extranodal growth pattern (p=0.05) to be 
independent predictors of longer DFS. The association of the location of lymph node metastasis with 
DFS was not statistically significant in the multivariable model (Table 4).
 The estimated 5-year DSS was 28%, 34%, and 66% for groin, axilla, and neck, respectively 
(Figure 1b). Variables associated with DSS in univariate analysis were the location of nodal metastasis, 
extranodal growth pattern, L/N ratio, and the size of the largest nodal metastasis (Table 3). The 
multivariable model for DSS revealed neck site of metastasis (p=0.02) (Table 4) and a lower L/N ratio 
(p<0.001) to be significantly associated with better survival.
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95% CI              p-value
DSS
HR 95% CI p-value
Location primary melanoma
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Interval primary– nodal metastasis (years)
  Continuous  0.95 0.90-1.01 0.11 0.90 0.88-1.01 0.09
Location metastasis
  Groin























No of involved nodes  
  Continuous
  N1 (1)
  N2 (2-3)




































Size of the lymph node metastasis (cm)
  Continuous 
  <3.0












All variables with p<0.10 were included in multivariable model along with sex, age, Breslow thickness, and 
ulceration.
Abbreviations: DFS, disease-free survival; DSS, disease-specific survival.
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Figure 1a/b. Kaplan-Meier for disease-free survival (1a) and disease-specific survival (1b) according to location 
of lymph node metastasis
86
Melanoma follow-up and prognostic factors in surgery for nodal recurrences
Table 4. Multivariable Cox regression analysis of prognostic value of nodal metastasis location for disease-free 




% (95% CI) 
Multivariablea 





Groin 12.1 (2.1-22.1) 1 (reference) 28.2 (16.0-40.3) 1 (reference)
Axilla 27.1 (13.4-40.8) 0.94 (0.59-1.50) 0.78 33.6 (19.9-47.3) 0.98 (0.60-1.60) 0.93
Neck 49.2 (26.5-71.9) 0.48 (0.22-1.09) 0.08 66.3 (43.2-89.4) 0.27 (0.10-0.79) 0.02
a Hazard ratio for DFS adjusted for presence of ulceration, extranodal growth pattern, and ratio of involved/total 
nodes (L/N ratio).
b Hazard ratio for DSS adjusted for sex and L/N ratio.
Abbreviations: DFS, disease-free survival; DSS, disease-specific survival.
Discussion
Analysis of 149 melanoma patients undergoing curative TLND showed the 5-year DSS to be 37% for the 
entire group, which is similar to percentages reported in the literature.5, 21 Univariate and multivariable 
analysis revealed differences in prognosis for metastasis in the groin, axilla, or neck. Specifically, nodal 
metastasis located in the neck was associated with significantly better DSS. No statistically significant 
difference was found for frequency of distant metastases as the first site of recurrence: groin group 
78%, axilla group 76%, and neck group 55% (p=0.26). 
 In present study, significant prognostic factors for survival in univariate analysis were site of 
nodal metastasis, extranodal growth pattern, L/N ratio, and size of the largest nodal metastasis. 
Besides neck site of nodal metastasis, low L/N ratio was found to be an independent predictor for 
better DSS which is in agreement with recent literature.18-20 Primary melanoma characteristics were 
not associated with survival, which is consistent with the study of 441 Stage IIIB-C melanoma patients 
by Balch et al.3, 5 Finding longer survival for neck site metastasis seems contrary to the observation that 
head and neck melanomas have a worse prognosis than melanomas at other sites.12, 13 However, the 
literature currently lacks specific studies regarding the prognostic value of the site of nodal metastasis. 
Moreover, a recent study on the outcome of TLND in stage III melanoma patients with an unknown 
primary melanoma did notice a survival benefit for patients with a neck metastasis compared to groin 
or axillary metastasis.21
 The better prognosis for patients with neck metastasis could be explained by earlier detection of 
nodal metastasis, resulting in a smaller tumor burden at time of the TLND, and of recurrent locoregional 
disease in the neck, because of the more superficial and notable position of nodes compared to those 
in the groin or axilla. Supporting this, we found that the lymph node metastases in the neck group were 
significantly smaller than in the groin and axilla groups. In addition, there is a tendency for patients 
in the neck group to present more frequently with local or locoregional recurrence as the first sign of 
progressive disease, rather than distant disease, compared to the groin and axilla groups. However, 
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with the current study size, this tendency did not reach statistical significance.
 To evaluate the outcomes of nodal metastasis at different locations without the detection benefit 
of superficial macrometastasis, we performed a subanalysis of data of 117 patients that underwent 
CLND shortly after positive SLNB in a recently published study by de Vries et al.22 This subanalysis 
showed a 5-year DSS of 63%, 68 %, and 75% for the groin, axilla, and neck groups respectively. Although 
the difference in survival was not statistically significant, the more favorable number for metastasis 
at the neck site is notable. Therefore we concluded that the detection benefit alone, even though 
it proved to be important, could not fully explain the survival difference. Another hypothesis that 
could explain our findings is the effect of a more extensive lymphatic system in the neck region, which 
could keep metastases from hematogenous spread. In this case, we would expect differences in the 
percentage of patients that were upstaged with PET or CT after presenting with palpable lymph node 
metastases at the different locations. However, in a previous study we found no differences in the 
percentage of upstaging between the groups of patients with groin, axilla or neck metastases (18.3% 
groin, 31.3% axilla, and 23.3% neck; p=0.12).14 The exact mechanisms underlying better survival thus 
remain unknown. However, possibilities include differences in the behavior of the primary melanoma, 
a lower detection threshold, immunological advantages of the nodal basin in the neck, and dissection 
effects. 
 The findings of this study are limited by the rather small group of patients that underwent 
TLND of the neck (n=22). Therefore, definitive establishment of the more favorable prognosis for 
macrometastasis when located in the neck needs confirmation by larger series.  
 In conclusion, this study showed better prognosis after TLND for stage IIIB-C melanoma when 
the lymph node metastasis is located in the neck compared to axillary and groin sites. 
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ABSTRACT
Introduction. In melanoma patients with nodal macrometastases, distinction between good and poor 
prognosis is based on the presence of primary melanoma ulceration or metastatic involvement of 4 or 
more lymph nodes in the 7th AJCC classification. We hypothesized that biomarkers would increase the 
accurateness of staging in these patients. The aim was to assess and compare the prognostic impact 
of biomarkers S-100B and LDH and to determine the best timing of their measurement in stage IIIB-C 
melanoma. 
Methods. A total of 119 patients underwent therapeutic lymph node dissection (TLND) for nodal 
macrometastases with serum S-100B and LDH level measurements preoperatively. In 75 of them, 
S-100B and LDH was also measured on postoperative days 1 and 2. S-100B and LDH levels on days 
0, 1, and 2 were compared for their association with disease-free survival (DFS) and disease-specific 
survival (DSS). 
Results. At a median follow-up of 17 (range 1-89) months, S-100B levels at all time points were associated 
with DFS. In multivariable analysis, preoperative S-100B and S-100B measured on day 2 showed the 
strongest association with DFS (HR=2.55, p=0.007 and HR=3.80, p=0.01). For DSS, the preoperative 
S-100B level was the strongest independent predictor (HR=2.81, p=0.01). LDH measurements showed 
a significant association with DSS in univariate analysis, only when measured preoperatively (HR=2.46, 
p=0.01). In multivariable analysis, LDH measurement was not associated with melanoma prognosis.
Conclusion. The S-100B level measured preoperatively is, in contrast to LDH, one of the most 





The incidence of melanoma in the western world is on the rise. In the United States, estimated more 
than 70,000 people will be diagnosed with melanoma in 2012.1 The majority of patients present initially 
with Stage I or II melanoma and 33-50% of these patients are diagnosed with Stage IA disease.2, 3
 Unfortunately, approximately one out of five melanoma patients develops recurrent disease. 
These recurrences occur locally or in-transit in 20–28%, distant in 15–50%, but most frequently 
in regional lymph nodes (26–60%).4 Patients with palpable lymph node metastases, American 
Joint Committee on Cancer (AJCC) stage IIIB-C, have a 5-year survival rate of 43% when a regional 
therapeutic lymph node dissection (TLND) of the affected basin is performed.5 In patients with 
palpable lymph node metastases, distinction between a relatively good and poor prognosis (stage IIIB 
and IIIC, respectively) is, in the current 7th AJCC melanoma classification, based on the presence of 
primary melanoma ulceration or metastatic involvement of 4 or more lymph nodes. 
 For melanoma, two biomarkers have been extensively studied: earlier Lactate Dehydrogenase 
(LDH) and lately S-100B.6 LDH was already implemented in the AJCC system in 2001 to classify stage 
IV patients. The melanoma associated molecule S-100B was found to be correlated with melanoma 
progression in both stage III and IV disease7, 8. Previously our institution established that elevated 
levels of serum S-100B are associated with a decreased disease-free survival in melanoma patients 
presenting with palpable nodal metastases (stage IIIB-C).9 Also Bouwhuis et al. and Tarhinni et al. 
proved S-100B to be a prognostic marker for survival in melanoma.10, 11 However, today’s use of 
biomarkers in melanoma still only includes LDH as a staging marker in AJCC stage IV disease and the 
best timing of perioperative S-100B measurements is unknown. 
 We hypothesized that biomarkers could increase the accurateness of staging in patients with 
nodal macrometastases (currently AJCC stage IIIB–C). Identification of patients with macrometastases 
with high risk for recurrence seems to become more and more important with the recent breakthroughs 
in medical treatment of recurrent melanoma (e.g., with ipilimumab and vemurafenib).12,13 In the 
very near future, biomarkers can be used to select high risk stage III patients for adjuvant systemic 
treatment in new trials. For example, the upcoming COMBI-AD trial will study the effect of adjuvant 
MEK and BRAF inhibition in surgically treated stage III melanoma patients.14 
 The aim of the present study was to (re)assess and compare the prognostic impact of the 
biomarkers S-100B and LDH in current stage IIIB-C melanoma at our institution with a larger patient 
cohort and prolonged follow-up. Also, different time points of perioperative S-100B and LDH 
measurements were compared for their association with melanoma prognosis.
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Methods
All consecutive melanoma patients with palpable and cytologically proven lymph node metastases 
diagnosed at and referred to the Division of Surgical Oncology of the University Medical Center 
Groningen (UMCG), the Netherlands, between 2004 and 2011 underwent staging with whole-body 
FDG-PET and/or spiral-CT. Patients with distant metastases or more than one affected lymph node 
basin were excluded from this study. All patients were informed about their stage of disease, type 
of regional nodal dissection, and potential perioperative complications, according to the UMCG 
standards. All stage IIIB-C melanoma patients underwent TLND and had S-100B and LDH biomarker 
levels measured one day prior to surgery and on postoperative days 1 and 2 if patients were still 
hospitalized. 
 A level I-III axillary dissection was performed with resection of the minor pectoral muscle. Groin 
dissection comprised superficial (inguinal) and deep (iliac and obturator) lymph node dissection with 
sartorius muscle transposition.15 Neck dissection included radical removal of lymph nodes in
levels I-III, I–V, and II-V, including the posterior compartment depending on indication. A subtotal 
dissection of the parotid gland was performed depending on the localization of the lymph node 
metastasis and the primary site. Patients with positive lymph nodes larger than 3 cm, 3 or more positive 
lymph nodes, and/or extranodal growth pattern received adjuvant radiotherapy (45–60 Gy).16,17
 All patients with recurrent disease after TLND were discussed in a multidisciplinary melanoma 
conference and received what is termed a ‘tailored treatment’ i.e. surgery, radiation, and/or systemic 
treatment according to the present standard or experimental treatment protocols. 
Biomarker assay and reference cutoff
S-100B levels were calculated on the basis of a calibration curve and checked against internal 
standards with a known concentration of S-100B. Initially the Diasorin S-100b assay (Sangtec 100 
Diasorin, Saluggia, Italy) was performed on the Advantage immunoassay platform (Nichols). However, 
this Nichols analyzer was abruptly withdrawn from all laboratories worldwide, forcing laboratories 
to change to other assays. Our laboratory changed to and validated the manually performed S-100B 
assay of the same firm (Diasorin). In this validation process a new cut-off was determined by analyzing 
S-100B levels of 120 healthy individuals according to the CLSI C28A2 guideline. This resulted in a 
reference cutoff point of 0.15 µg/l for measurements before July 2006 and 0.20 µg/l for measurements 
after July 2006 at our institution. 
 LDH was analyzed routinely by means of Roche Modular (Hitachi) with an enzymatic activity 




The clinicopathologic characteristics of all 119 patients and their primary melanomas (age and sex, 
histologic subtype, unknown primary, Breslow thickness, Clark level, ulceration, mitotic rate, and 
regression), and the pathologic characteristics of their TLND specimens (total number of nodes, 
number of involved nodes, lymph node (LN) ratio, size of the largest nodal metastasis, and extranodal 
growth pattern) were analyzed for their association with disease-free survival (DFS) and disease-
specific survival (DSS) using univariate Cox regression analysis. Subsequently, the prognostic value of 
S-100B and LDH levels on the preoperative and postoperative (day 1 and 2) days was compared in the 
75 patients who had complete data at all time points. Also, the prognostic value of the perioperative 
biomarker change, from preoperative to day 2, was assessed. Biomarker levels that were significantly 
associated with DFS and DSS in univariate analysis were entered in a multivariable model together 
with clinicopathologic factors that were associated with DFS and DSS on a 5% significance level. 
Kaplan-Meier curves were created for the strongest prognostic combinations of the biomarkers and 
their measurement timing. Statistical analysis was performed using the SPSS software package (SPSS 
18.0, Chicago, Illinois, USA).
Results
In a total of 119 patients, 56 females and 63 males with a median age of 58.3 (range 24.7-93.2) 
years underwent a TLND with curative intent. In the majority of patients (55.5%) a groin dissection 
was performed, in 34.5% an axillary dissection, and in 10.1% a neck dissection. (Table 1) Following 
histopathological analysis, 53 patients were staged as IIIB and 66 as stage IIIC according to the current 
7th AJCC melanoma classification. The median follow up of all patients was 17 (range 1-89) months. For 
the patients still alive the median follow-up was 32 (range 3-89) months.
Clinicopathological characteristics associated with DFS and DSS
In univariate analysis of 119 patients, the presence of ulceration, the number of involved nodes, the 
LN ratio, and the presence of extranodal growth showed significant association with both decreased 
DFS and DSS. Male sex and the total number of harvested nodes were the only characteristics that 
were associated with a decreased DSS. A trend for improved DFS and DSS was found for neck site of 
nodal metastases compared to the axillary and groin sites. (Table 1)
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Table 1. Characteristics of 119 patients undergoing therapeutic lymph node dissection and their association 
with melanoma prognosis

















  Continuous (median, range) 58.3 (24.7-93.2) 1.01 (0.42) 1.01 (0.16)
Histologic type 
  Superficial spreading 
  Nodular 
  Acral lentiginous
































  Continuous (median, range) 2.1 (0.5-16.0) 1.02 (0.69) 1.03 (0.56)
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Table 1 continued. Characteristics of 119 patients undergoing therapeutic lymph node dissection and their 
association with melanoma prognosis





Total number of nodes
  Quantitative (median, range) 16 (3-70) 0.98 (0.27) 0.96 (0.04)
Number of involved nodes 
  Quantitative (median, range) 
  N1 (1)
  N2 (2-3)









1.08 (0.001) 1.07 (0.04)
LN ratio
  Continuous (median, range) 12 (1-100) 1.02 (<0.001) 1.01 (0.005)









Size of metastasis (cm)  











  No 









Abbreviations: DFS, disease-free survival; DSS, disease-specific survival; LN, lymph node 
Italic printed items are descriptive and not included in univariate analysis. 
All characteristics with p<0.05 were included in the multivariable analysis in table 2 and 3.
Association of S-100B and LDH at different time points with DFS and DSS
Complete biomarker data was available for analyses in 75 out of 119 patients. For S-100B, elevated 
serum levels were found in 36.0%, 18,7%, and 9.3%, when measured preoperatively, on day 1, and 
on day 2, respectively. As shown in Table 2, the S-100B levels at all time points were associated with 
DFS in both univariate and multivariable analysis. Preoperative S-100B and S-100B measured on 
day 2 showed the strongest association with DFS in multivariable analysis (hazard ratio [HR] 2.55, 
95 % CI 1.29–5.06, P = 0.007 and HR 3.80, 95 % CI 1.38–10.46, P = 0.01, respectively). For DSS, both 
preoperative S-100B and the S-100B level measured on day 2 were significant predictors in univariate 
analysis. In multivariable analysis, the preoperative S-100B level showed the strongest association 
with DSS (HR 2.81, 95 % CI 1.23–6.42, P = 0.01). (Table 2)
 The perioperative change of S-100B showed significant association with DFS and DSS in univariate 
and multivariable analysis, especially for patients in whom serum levels remained normal compared 
to patients in whom S-100B became normal (Table 2). Five patients in whom S-100B levels remained 
elevated showed significantly worse DFS. Two of them presented with a regional recurrence and three 
with distant disease.
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 For LDH, as shown in Table 2, elevated levels were found in 21.3%, 5.3%, and 8.0%, when 
measured preoperatively, on postoperative day 1, and on postoperative day 2, respectively. The LDH 
levels were only associated with DSS in univariate analysis when measured preoperatively (HR 2.46, 
95 % CI 1.24–4.88, P = 0.01). In multivariable analysis, preoperative LDH lost its significant association 
with DSS (HR 1.48, 95 % CI 0.68–3.23, P = 0.33). (Table 2)
 Because preoperative measurement of both S-100B and LDH showed the strongest association 
with melanoma prognosis, further analysis was performed on all 119 patients who all had complete 
preoperative biomarker data.
Table 2. Biomarkers LDH and S-100B levels on different time points and their association 
with melanoma prognosis in 75 patients














































Perioperative LDH change 
  Became normal 
  Remained elevated
  Became elevated  
































































Perioperative S-100B change 
  Became normal 
  Remained elevated
  Became elevated  

























a Hazard ratio for DFS adjusted for presence of ulceration,  LN ratio, and extranodal growth.
b Hazard ratio for DSS adjusted for sex, presence of ulceration, LN ratio, and extranodal growth.
Abbreviations:  DFS, disease-free survival; DSS, disease-specific survival; LDH, lactate dehydrogenase.
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DFS and DSS rates according to strongest predictive S-100B and LDH measurement 
According to preoperative S-100B levels, 5-year DFS was 37.8% and 5-year DSS was 47.4% for patients 
with normal preoperative levels, which was significantly better than the 5-year DFS of 6.6% and the 
5-year DSS of 28.3% for patients with elevated S-100B levels (Table 3 and Figure 1). 
 Although no significant associations with DFS and DSS were found for LDH levels, some 
differences in survival percentages were seen between patients with normal and elevated preoperative 
LDH levels. In patients with normal preoperative LDH levels 5-year DFS was 27.1% and 5-year DSS was 
48.0% compared to 18.6% and 20.5% for patients with elevated LDH levels (Table 3 and Figure 2).
Multivariable analysis of clinicopathological and biomarker characteristics associated with 
DFS and DSS
In 119 patients, multivariable analysis revealed presence of ulceration (HR 1.93, 95 % CI 1.19–3.13, P = 
0.008), higher LN ratio (HR 1.01, 95 % CI 1.00–1.02, P = 0.007), and preoperative elevated S-100B levels 
(HR 2.04, 95 % CI 1.26–3.31, P = 0.004) to be independent predictors of decreased DFS. For DSS, male 
gender (HR 1.93, 95 % CI 1.10–3.39, P = 0.02) and preoperative elevated S-100B levels (HR 1.82, 95 % 
CI 1.02–3.22, P = 0.04) revealed to be only independent predictors of worse prognosis. Preoperative 
LDH levels did not show a significant association with DFS and DSS on multivariable analysis. (Table 3)
Table 3. Multivariable Cox regression analysis of prognostic significance of preoperative biomarker values in 
119 melanoma patients undergoing therapeutic lymph node dissection
DFS DSS
Preoperative 











































a Hazard ratio for DFS adjusted for presence of ulceration, LN ratio, and extranodal growth.
b Hazard ratio for DSS adjusted for sex, presence of ulceration, LN ratio, and extranodal growth.
Abbreviations: DFS, disease-free survival; DSS, disease-specific survival; LN, lymph node.
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Discussion 
The present study aimed to assess and compare the prognostic significance of serum S-100B and LDH 
levels measured at different perioperative time points in current stage IIIB-C melanoma patients who 
underwent TLND with curative intent. 
 In the United States, the biomarker S-100B is rarely used in melanoma research and not 
widely accepted in melanoma care. In contrast, in Europe the marker, which seems to reflect tumor 
load17, is increasingly being studied and used in clinical practice to define extent of disease in patient 
management. S-100B is located in the cytoplasm of melanoma cells and cell death probably results 
in elevated serum levels of S-100B.6, 19 S-100B levels were already shown to be significantly correlated 
with the stage of disease, with normal levels in AJCC stage I and II, elevated levels in a substantial 
proportion of stage III patients, and highest levels in stage IV disease.20, 21 However, S-100B seems to 
Figure 1. Disease-free and disease-specific 
survival according to S-100B level at day 0
Figure 2. Disease-free and disease-specific 
survival according to LDH level at day 0
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lack sensitivity to justify its use as screening marker for recurrences in stage I and II disease, in an era 
with still limited treatment options for distant recurrences.22 In stage IV patients S-100B levels predict 
response to chemotherapy23. For stage III melanoma, preoperatively measured S-100B was previously 
reported by our group to be associated with DFS9. However, this was studied in a much smaller cohort 
of 57 patients with a relatively short follow-up. Moreover, postoperative S-100B measurements, as 
well as LDH levels, were not analyzed and compared for their prognostic significance in that study.
 The results of this study reveal that, in stage IIIB-C patients, S-100B levels show a strong 
association with melanoma prognosis in contrast to LDH levels. Preoperative measurements show 
stronger association than measurements on day 1 or 2. For DSS, male gender and preoperatively 
elevated S-100B were both independent predictors of worse prognosis. Moreover, preoperative 
measurements of S-100B showed to be the strongest independent predictor of DFS. 
 When preoperatively elevated, biomarker levels decreased in the majority of patients, 
confirming that elevated levels probably reflect regional tumor load. The best timing of both S-100B 
and LDH measurement to predict prognosis was the day before TLND, although LDH did not show 
any association with DFS or DSS in multivariable analysis. When measured preoperatively, S-100B 
was the strongest independent predictor of melanoma prognosis. Other measurements of prognostic 
significance were S-100B measured on day 2 and the change in S-100B level seen in the perioperative 
period. However, the latter seems predominantly an effect of the preoperative S-100B measurement, 
because differences were especially found between patients who had S-100B levels that remained 
normal and patients who had levels that became normal (i.e. were elevated preoperative). S-100B 
levels that remained elevated after nodal dissection in 5 patients probably indicate occult distant 
disease missed by preoperative FDG-PET/CT screening or any residual regional tumor load, which 
accounts for the decreased DFS of those patients (Table 2). Strangely, these patients did not suffer a 
decreased DSS. Maybe the elevated S-100B levels lead to closer monitoring in follow-up and possibly 
earlier aggressive surgical or medical treatment of recurrences.
 The most obvious cause for the strong prognostic value of preoperative S-100B values is the 
representation of melanoma tumor load.18 In addition, a second way in which S-100B levels could be 
linked with melanoma prognosis is outlined by some recent studies.24,25 These studies suggest that the 
presence of an elevated S-100B level itself induces disease progression by suppressing the p53 tumor 
suppressor protein. Based on the present data, however, we are not able to determine which of those 
two theories is (most) responsible for the prognostic value of S-100B levels.
 Other studies that compared the prognostic significance S-100B and LDH were predominantly 
conducted in melanoma patients with distant metastases (AJCC stage IV).  While some of those studies 
found both S-100B and LDH to be strong prognostic factors21, 26 and one study found LDH to be the 
strongest predictor of stage IV melanoma prognosis27, other studies demonstrate that S-100B is the 
strongest prognostic factor and superior to LDH in patients with distant metastases28-31. 
 A limitation of the present study, which also shows superiority of S-100B over LDH for estimation 
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of melanoma prognosis, is the limited number of patients (n=75) with complete biomarker data for 
both S-100B and LDH. This disabled comparison of the prognostic significance of the biomarkers in 
all 119 patients. However, this is the only available optimally PET-CT staged cohort of stage IIIB-C 
melanoma patients in which perioperative S-100B and LDH levels were compared for their prognostic 
value. Also, the heterogeneity in treatment modalities used in case of a recurrence, as well as the 
recent introduction of new treatments for stage IV melanoma, could have influenced the DSS survival 
data, making interpretation of the associations with DSS more complicated than interpretation of DFS 
data. 
 Future perspectives, if the present results are confirmed in larger series, comprise more accurate 
staging of melanoma patients with nodal macrometastases by integration of the biomarker S-100B in 
melanoma systems like the AJCC staging manual. Moreover, patients with nodal macrometastases 
who are burdened with a poor prognosis, as indicated by preoperatively elevated S-100B levels, could 
be selected for new trials using adjuvant or neoadjuvant medical treatment with new promising 
agents like ipilimumab and vemurafenib.12,13 Selection of patients who are most likely to benefit from 
these drugs seem profitable, before administering these potentially toxic and still very expensive 
systemic drugs to stage III patients. In addition, it seems logical to include the S-100B biomarker as a 
stratification factor in new trials that investigate (neo)adjuvant treatments in stage IIIB–C melanoma 
patients.
 In conclusion, the S-100B level measured preoperatively is one of the most important 
independent predictors of the prognosis and superior to LDH in patients undergoing TLND for AJCC 
stage IIIB-C melanoma. 
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ABSTRACT
Introduction. In melanoma, about one in five patients develops distant metastases and suffers a 
very poor prognosis. Common treatment options comprise surgery, systemic medical therapy, and 
radiotherapy, depending on the number, location, and the resectability of distant metastases. Previous 
studies suggested that surgery should be the first choice of treatment whenever complete surgical 
removal is feasible.  However, the proportion of patients that are candidates for this approach is not 
clear. The aim of the present study was to evaluate the extent of disease and resectability of melanoma 
patients presenting with stage IV disease at our institute. 
Methods. All melanoma patients diagnosed with stage IV between January 2011 and August 2012 
were assessed for extent and resectability of their disease.
Results. About half of 70 assessed patients had seven or more metastases at diagnosis, whereas 13 
patients had only one metastasis. The vast majority (n=55, 78.6%) was ineligible for complete surgical 
resection. Six patients did receive complete surgery as initial stage IV treatment and in 9 patients 
incomplete surgery was performed. Widespread disease (n=44) and unresectable metastasis (n=11) 
were the most common reasons for refraining from complete surgery. 
Conclusion. The results of the present study show that only a small proportion of patients diagnosed 





In melanoma, about one in five patients develops distant metastases and suffers a very poor prognosis. 
These patients are classified as stage IV according to the American Joint Committee on Cancer (AJCC) 
staging manual. The one-year survival rate of patients diagnosed with stage IV melanoma varies 
between 33% and 66%, depending on lactate dehydrogenase (LDH) level and the location of the 
metastases.1  
 For stage I, II, and III melanoma, treatment regimens are well defined and consist of surgical 
resection of the primary melanoma and nodal metastases if present.2, 3 For stage IV melanoma different 
treatment strategies are practicable. Depending on the number, location, and the resectability of 
distant metastases, common treatment options comprise surgery, systemic medical therapy, and 
radiotherapy. 
 In previous studies, the best survival rates have been found for stage IV patients who underwent 
complete surgical removal, i.e. total resection of all radiographic and clinically evident metastases. 
Small retrospective series have established that patients in whom complete surgical removal is 
feasible have a 5-year survival rate of 15-28%4-9, which is superior to the 5-10% found for patients 
who receive systemic medical therapy10, 11. The prospective series of the Southwest Oncology Group 
showed a 25% 5-year survival in 64 patients whose metastases had been completely resected12. 
Even better survival rates have been found during the MMAIT-IV trial, which combined surgery with 
immunotherapy: 5-year survival was 40-45%13. These results suggest that surgery should be the first 
choice of treatment for stage IV melanoma whenever complete surgical removal is feasible. 
 After analysis of 291 stage IV patients in the Multicenter Selective Lymphadenectomy Trial 
(MSLT-I), which also suggested superiority of surgery over systemic medical therapy as initial treatment 
for distant melanoma14, a phase II trial was launched by Morton et al in 2009. This multicenter 
randomized trial initiated by the John Wayne Cancer institute (JWCI) aimed to compare surgery and 
systemic medical therapy as initial treatment for completely resectable stage IV melanoma, and 
additionally planned to study the effect of adjuvant immunotherapy.15 The inclusion criteria of this 
trial required patients to have distant disease that could be completely surgically removed.
 In our experience however, most stage IV melanoma patients are treated with systemic medical 
therapy despite the intention to perform surgery whenever feasible. Therefore, we hypothesized that 
the incidence of completely resectable stage IV melanoma patients in our patients is low.
 The present study aimed to evaluate the extent of disease and resectability of melanoma patients 
presenting with stage IV disease at our institute, in order to establish the incidence of completely 
resectable stage IV melanoma and to gain insight in factors that impede complete resection. 
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Methods
All consecutive melanoma patients with stage IV melanoma diagnosed at and referred to the 
Department of Surgical Oncology of the University Medical Center Groningen (UMCG), the 
Netherlands, between January 2011 and August 2012, were included in this study. Also, stage IV 
patients referred to the Department of Medical Oncology who were considered for surgery and 
therefore presented in a multidisciplinary conference were included. The UMCG is a tertiary referral 
center for melanoma patients and covers the north-eastern part of the Netherlands (Groningen, 
Friesland, Drenthe, Overijssel: 2,860,000 inhabitants) for specialized melanoma care. The Department 
of Surgical Oncology is visited by approximately 200 new melanoma patients annually.
 At stage IV diagnosis, the extent and resectability of distant metastases and patient eligibility 
for JWCI stage IV trial was assessed. All patients were staged and their extent of disease determined 
by PET/CT or CT scanning and measurement of serum LDH and S-100B levels, except for patients who 
needed emergency surgery. Brain MRI was not routinely performed. Stage IV diagnosis was confirmed 
by histopathological analysis whenever possible. Extent of disease, resectability and initial treatment 
modality were determined in a multidisciplinary melanoma conference, attended by a radiologist, a 
pathologist, a surgical oncologist, a medical oncologist, and a radiotherapist. 
 Details of the patients, their initial stage of disease, the extent of disease at stage IV diagnosis, 
stage IV treatment, and reason why surgery was not performed were collected in a database. 
Unresectable disease was defined as one or more metastases that could not be surgically removed due 
to their relation with vital structures. Widespread disease was defined as seven or more metastases or 
involvement of four or more organs. LDH was considered elevated when the level was above 375 U/L 
(1.5x the upper limit of normal in our center).
Statistics
Frequencies and percentages were used for data presentation. Differences in estimated survival rates 
were analyzed using Kaplan-Meier curves and the Log Rank test with a significance level of 5%. Survival 
time was calculated from the date of stage IV diagnosis to the date of death. Statistical analysis was 
performed using the SPSS software package (SPSS 20.0, Chicago, Illinois, USA). 
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Results
Characteristics 
A total of 70 patients were diagnosed with stage IV melanoma, of which 42 were male. The median 
age at stage IV diagnosis was 56.2 (range 19.2-82.6) years. The median time interval between primary 
melanoma and diagnosis of distant metastasis was 3.3 (range 0-23.6) years. According to the AJCC 
staging manual, the vast majority of patients suffered M1c disease (Table 1). 
Table 1. Characteristics of 70 melanoma 
patients at stage IV diagnosis
Table 2. Extent of stage IV melanoma at time 
of diagnosis
Characteristic n (%) Extent of distant disease n (%)
Sex
  Female 








  III 
  IV
  Unknown










































  ≥7 
Location involved*
  Brain
  Bone 
  Lung 
  Abdominal

































Abbreviation: AJCC, American Joint Committee 
on Cancer. 
*Various patients had more than one location 
involved.  
Extent of distant disease 
Most patients had two or more organ sites affected by metastases and thirteen patients had four or 
more organs involved. In 28 patients (40.0%) only a single organ was affected by metastases (Table 
2).  Most frequently, the latter group of patients had brain (n=8), pulmonary (n=7), and abdominal 
involvement (n=9).  
 Overall, about half of patients had seven or more metastases at diagnosis, whereas thirteen 
patients had only one metastasis found. The abdominal organs and lungs were the most frequently 
affected by metastases. (Table 2)
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Surgery as initial treatment stage IV
The vast majority of patients (n=55, 78.6%) was ineligible for complete surgical resection. Six patients 
did receive complete surgery as initial stage IV treatment, and in nine patients incomplete surgery was 
performed. Widespread disease (n=44) and unresectable metastasis (n=11) were the most common 
reasons for refraining from complete surgery. (Table 3)
 The six patients who underwent complete surgical resection exhibited the following metastases: 
a single pulmonary metastasis, two subcutaneous metastases, a single metastasis in the gallbladder, 
a single metastasis in the small bowel, a cerebral metastasis, and a single metastasis in the skull, 
respectively. Incomplete surgical resection was performed for varying reasons, like an invagination, 
bleeding or bowel obstruction due to one of multiple abdominal metastases, debulking of a 
symptomatic cerebral metastasis, and diagnostic excision of a (sub)cutaneous lesion in the presence 
of multiple distant lesions.
Eligibility JWCI trial
As the majority of patients were not suitable for complete surgery, only six patients were screened 
for the JWCI stage IV trial. All six patients were found not eligible for the trial due to brain or bone 
involvement, inability to preoperatively confirm stage IV diagnosis by histopathology, subcutaneous 
metastasis of an unknown primary, elevated LDH level, or surgery already performed by other 
specialist before considering trial. (Table 3)
Table 3. Assessment of complete resectability and trial eligibility in 70 patients diagnosed 
with stage IV melanoma
Surgery as initial stage IV treatment n (%)
 Complete surgery performed  
 Incomplete surgery performed   











 Patient in poor condition











Reason not eligible for JWCI trial: n=6
 Brain/bone involvement 
 No preoperative histopathology possible 
 Subcutaneous metastasis of unknown primary
 Physician unaware of trial






Abbreviations: JWCI, John Wayne Cancer Institute; LDH, Lactate dehydrogenase.
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Survival according to initial stage IV treatment
The overall median survival was 14.6 months and the estimated 1-year survival rate was 51.0%. 
The one-year survival rates of patients who were treated by surgery, systemic medical therapy, 
radiotherapy and no antitumor therapy at al were compared. Patients who were not treated for stage 
IV melanoma had a significantly worse estimated one-year survival than patients that were treated 
with a type of antitumor therapy (0% vs 55.5%, p<0.001). There seemed to be no significant survival 
differences between the different stage IV treatment modalities, although small groups and limited 
follow-up make this comparison difficult. (Figure 1) The one-year survival rates were 75%, 49%, and 
80% for surgery, systemic medical therapy, and radiotherapy, respectively (p=0.70). (Table 4)
Table 4. Survival from diagnosis according to performed treatment modality
Initial stage IV treatment n One-year survival
Surgery
  Complete surgery 
  Incomplete surgery







  DTIC + BRAF
  BRAF only







  Radiotherapy alone




No stage IV therapy 8 0%
Abbreviations: SMT, systemic medical therapy; DTIC, dacarbazine; BRAF, vemurafinib.  
Figure 1. Stage IV survival according to performed initial treatment modality
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Discussion
Stage IV melanoma is still difficult to cure and suffers a poor prognosis. So far, surgery is almost the 
only treatment that can provide cure. Survival rates are promising in a selected patient category in 
which complete surgical resection is possible.  
 The results of the present study reveal that only a small proportion of patients qualifies for 
complete surgery at time of stage IV diagnosis. Less than 10% of patients who presented with stage IV 
melanoma at our institution had completely resectable disease. 
 Higher rates of resectability found in previous studies5, 8, 14 might be due to earlier detection of 
distant disease. In the Netherlands, current guidelines, which are also practiced at our institution, only 
recommend diagnostic imaging in follow-up if distant disease is suspected because of present clinical 
signs, which is the most minimalistic approach compared to other countries.16 Melanoma guidelines 
in Germany17 recommend usage of ultrasound, chest X-rays, and biomarkers in follow-up, which could 
account for the 25% of resectable patients found by Meyer et al8. Also, patients who participate in 
clinical trials like MSLT-I, like those in the study of Howard et al.14, could receive a more thorough 
follow-up than patients who are treated in the regular follow-up. This more intense follow-up could 
account for earlier detection of distant disease, resulting in higher resectability rates. 
 Melanoma biomarkers S-100B and LDH could even further narrow the selection of patients who 
could potentially benefit from complete surgical resection. A study of Weide et al. revealed that the 
great beneficial effect of complete metastasectomy on survival was only found in stage IV patients who 
had both normal S-100B and LDH levels.18  If one of the two biomarkers was elevated, which was most 
frequently S-100B, the survival benefit of complete metastasectomy nearly vanished. If both S-100B 
and LDH were elevated, there was no survival benefit at all for patients that underwent complete 
metastasectomy compared to other therapies. Therefore, we hypothesize that stage IV melanoma 
patients with elevated S-100B levels, as an indicator of extensive metastatic spread, will not benefit 
from complete metastasectomy, particularly if LDH levels are elevated too. 
 The 1-year survival rate of 51.0% and median survival of 14.6 months found for stage IV disease 
in the present study is similar to rates reported in literature.1 Although median survival rates did not 
differ between the various initial treatment modalities, one cannot draw definite conclusions about 
treatment effectiveness because of the low number of patients, limited follow-up, and the presence 
of confounding by indication. 
 The multicenter randomized trial initiated by the JWCI in 2009 aimed to definitively determine 
which initial treatment modality is superior for resectable stage IV melanoma. However, low accrual 
of patients resulted in termination of the trial in September 2012. This trial termination underscores 




In conclusion, the results of the present study show that only a few of the patients diagnosed with 
stage IV melanoma are candidates for complete surgical resection. Limited available evidence suggests 
better survival following a surgical approach for this highly selected group of patients. 
 If future studies confirmed the superiority of surgery above systemic medical therapy as initial 
treatment for resectable stage IV disease, it would apply to a highly selected group, because stage 
IV melanoma seems only surgically resectable in a limited proportion of patients. Patients with 
unresectable stage IV melanoma will need new successes obtained with combinations of surgery with 
adjuvant or neoadjuvant systemic medical therapies. Not only adjuvant immunotherapy, as was aimed 
to be studied in completely resectable patients by the JWCI trial, but also neoadjuvant treatment with 
new promising agents like ipilimumab and vemurafenib19, 20 could improve the chances for curation in 
initially unresectable patients in the future. 
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Melanoma healthcare currently encounters various challenges, on the one hand driven by its 
increasing prevalence and demand on healthcare resources, on the other hand originating from its 
unpredictable and almost incurable dissemination to distant sites. This chapter discusses the different 
leads generated by the present thesis that can contribute to improvement of both the efficiency of 
melanoma care and the curative treatment of progressive melanoma. 
Bed rest after groin dissection
Lymph node dissection for stage III melanoma is accompanied by substantial morbidity, especially in 
case of a groin dissection.1-4 Historically, patients were prescribed a long period of strict bed rest in 
an attempt to keep the complication rate as low as possible. More recently, more and more centers 
moved to shorter bed rest regimens to reduce the risk for venous tromboembolic events and increase 
cost-effectiveness. In Chapter 2, in which the influence of bed rest regimens on the early complication 
rate after groin dissections has been studied, early complications occurred in 48.5% of patients. Early 
mobilization after 5 days did not significantly increase the early wound complication rate compared 
to 10 day bed rest regimens. These results justify clinical application of a 5 day bed rest regimen and 
encourage exploration of the effects of a 3, 2, or even one day bed rest protocols in the future. These 
shorter bed rest protocols can contribute to an increase in cost-effectiveness of the groin dissection 
for melanoma, thereby reducing the demand on healthcare resources.
Completion lymph node dissection in sentinel-node positive melanoma patients
Since the abandoning of elective lymph node dissections for melanoma in the nineties, the sentinel 
lymph node biopsy (SLNB) is being used to select sentinel-node positive patients for completion lymph 
node dissection (CLND). However, still 80% of these patients have no metastases found in the lymph 
nodes that are removed by CLND, so called non-sentinel nodes (NSNs). In Chapter 3 predicting factors 
for NSN positivity have been identified and the validity of the previously proposed non-sentinel node 
risk score (N-SNORE) has been assessed. Primary melanoma regression and the size of the largest 
sentinel node metastasis revealed to be independently associated with NSN positivity. After a slight 
modification, the N-SNORE scoring system has proved to provide a significant stratification of risk for 
NSN positivity. The selection of high risk patients using this scoring system could contribute to a more 
focused application of CLND in sentinel-node positive melanoma patients and lower unnecessary 
morbidity and costs.  
 Currently pending international trials are studying alternative treatment regimens for sentinel-
node positive patients. The second Multicenter Selective Lymphadenectomy Trial (MSLT-II) by Morton 
et al.5 compares CLND with nodal observation using ultrasound and performing a therapeutic lymph 
node dissection (TLND) only if nodal metastases become clinically manifest. The EORTC MINITUB 
registration study6 explores the efficacy of CLND omission in patients with minimal tumor burden in 
the sentinel node. 
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 If MSLT-II reveals that immediate CLND is superior to nodal observation for a subgroup of 
patients, strict patient selection will improve the quality of the treatment regimen for sentinel-node 
positive patients. Combining different independent predictors for NSN positivity will result in the most 
accurate selection, irrespective of whether the goal is to select patients for CLND omission or CLND 
performance. The use of melanoma biomarkers S-100B and Lactate dehydrogenase (LDH) for this 
patient selection has been explored in Chapter 4. This chapter has revealed that the biomarker S-100B 
is a strong predictor of NSN positivity and thus can complement risk scores to select sentinel-node 
positive patients for CLND omission in the future. 
Sentinel lymph node biopsy
SLNB has been widely accepted as an important prognostic procedure for patients with a melanoma 
having a Breslow thickness larger than 1 mm. SLNB with CLND for sentinel-node positive patients 
even seems to improve survival compared to nodal observation using ultrasound and therapeutic 
lymph node dissection when a metastasis becomes clinically apparent.7 In spite of these capabilities 
of SLNB, Chapter 5 reveals that still 75% of Dutch medical specialists do not consider the procedure 
as a standard diagnostic procedure for melanoma. They thereby agree with the content of the 2005 
national guideline, which states that this procedure should be reserved for patients who want to be 
optimally informed about their prognosis. Adjustment of both the Dutch medical specialists’ attitude 
and the Dutch guideline will be required if survival benefit through SLNB is established by pending 
trials.
Follow-up
The overall prevalence of melanoma patients continues to increase due to rising incidence rates and 
improved treatment outcomes. This has resulted in a rising demand on health care resources with 
more and more patients needing treatment and subsequent follow-up visits.8 The frequency of follow-
up visits has been widely debated for melanoma, but neither scientific evidence nor international 
consensus does exist. Overall, high frequency follow-up is currently recommended in countries with 
the highest melanoma incidence.9 In Chapter 5 the opinions of Dutch medical specialists reveal that 
the high-frequency schedules, as described by the current national melanoma guideline, could be 
reduced according to a substantial proportion of specialists. Reducing the frequency of follow-up 
schedules will partially solve the problem of the rising demand on healthcare resources.
 In order to obtain scientific evidence to establish new melanoma follow-up schedules, our 
center prospectively studies the feasibility and safety of a reduced follow-up schedule in the pending 
multicenter MELFO trial.10, 11
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Nodal metastases 
The regional control and survival of melanoma patients who develop clinically detectable nodal 
metastases is improved by performance of a TLND with or without adjuvant radiation therapy.12-17 
Even despite accurate preoperative staging by PET/CT scanning 5-year survival rates after TLND 
remain unsatisfactory: 29-52%. In Chapter 6 it is demonstrated that the anatomical site of nodal 
macrometastasis is an important predictor of this prognosis. Patients who undergo a TLND for nodal 
metastases in the neck were found to have a better disease-specific survival compared to axillary and 
groin sites. 
 Elaborating on previous studies that have shown the prognostic capacity of the preoperatively 
measured S-100B18, Chapter 7 has compared the prognostic impact of biomarkers S-100B and 
LDH and has determined the best timing of their measurement in stage IIIB-C melanoma. It 
showed that preoperatively S-100B is, in contrast to LDH, one of the most important independent 
predictors of melanoma prognosis in patients undergoing TLND for nodal macrometastases. These 
preoperative measured S-100B values enable more accurate staging of melanoma patients with nodal 
macrometastases when incorporated in melanoma staging systems. Moreover, patients with nodal 
macrometastases who are burdened with a poor prognosis, as indicated by preoperatively elevated 
S-100B levels, could be selected for new trials using adjuvant or neoadjuvant systemic medical 
treatment with new promising agents like ipilimumab and vemurafenib19, 20. 
Distant metastases
Stage IV melanoma is still difficult to cure and patients with distant metastases suffer a poor prognosis. 
So far, surgery seems the only treatment that can provide a cure. Survival rates are promising in the 
selected patient category in which complete surgical resection of all distant metastases is possible. 
However, as was established in Chapter 8, complete surgical resection of all metastases is only feasible 
in a small proportion of stage IV melanoma patients. If future studies confirmed the superiority of 
surgery above systemic medical therapy as initial treatment for resectable stage IV disease, it would 
only apply to this highly selected group. Patients with unresectable stage IV melanoma will need new 
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De zorg voor melanoompatiënten staat voor een aantal uitdagingen. Aan de ene kant zorgt de 
gestaag stijgende prevalentie van het aantal melanoompatiënten voor een moeilijk te vervullen 
vraag naar zorgmiddelen. Aan de andere kant blijft uitzaaiing van het melanoom naar plaatsen 
elders in het lichaam vrij onvoorspelbaar en bijna niet te genezen. In dit proefschrift werden studies 
beschreven die kunnen bijdragen aan de verbetering van zowel de efficiëntie van de melanoomzorg, 
als de behandeling en preventie van uitzaaiingen van het melanoom. In dit hoofdstuk worden de 
verschillende aanknopingspunten die dit proefschrift voortbrengt op een rij gezet en hun bijdrage aan 
de verbetering van de behandeling van melanoompatiënten besproken. 
Bedrust na lymfeklierdissectie
Een lymfeklierdissectie voor stadium III melanoom gaat gepaard met een aanzienlijke morbiditeit, vooral 
in het geval van de liesklierdissectie.1-4 Oorspronkelijk werd patiënten na deze procedure langdurig 
strikte bedrust voorgeschreven in een poging wondcomplicaties te beperken. Tegenwoordig zijn veel 
centra overgestapt naar een kortere periode van bedrust, om zo het risico op tromboembolische 
events te beperkten en de kosteneffectiviteit te vergroten. Hoofdstuk 2, waarin de invloed van 
bedrust op het optreden van vroege wondcomplicaties na liesklierdissectie werd onderzocht, liet bij 
48,5% een opgetreden wondcomplicatie zien. Vroege mobilisatie na 5 dagen bedrust gaf geen hoger 
risico op wondcomplicaties dan mobilisatie na 10 dagen bedrust. Deze resultaten rechtvaardigen de 
toepassing van een 5-daags bedrust protocol en geven de mogelijkheid het effect van nog kortere 
bedrust verder te onderzoeken. Deze kortere bedrust protocollen kunnen zorgen voor een toename in 
kosteneffectiviteit van liesklierdissecties bij melanoompatiënten.
Aanvullende lymfeklierdissectie bij schildwachtklier-positieve melanoompatienten
Sinds het verlaten van de electieve lymfeklierdissecties voor het melanoom in de jaren negentig wordt 
de schildwachtklierprocedure gebruikt om patiënten met positieve schildwachtklieren te selecteren 
voor aanvullende lymfeklierdissectie. Echter, bij 80% van deze patiënten worden geen metastasen 
gevonden bij histologisch onderzoek van de bij aanvullende klierdissectie verwijderde klieren 
(zogenaamde non-sentinel nodes). In Hoofdstuk 3 van dit proefschrift zijn voorspellende factoren 
voor non-sentinel node positiviteit geïdentificeerd. Tevens werd de non-sentinel node risk score 
(N-SNORE), die eerder in de literatuur werd beschreven, getoetst. Voorspellende factoren voor non-
sentinel node positiviteit waren regressie in het primaire melanoom en de afmeting van de metastase 
in de schildwachtklier. De N-SNORE bleek, na een kleine aanpassing, een goede risico-inschatting 
te geven van de kans op het vinden van metastasen in de aanvullende klierdissectie. Het op deze 
wijze identificeren van laag- en hoogrisico patiënten zou minder breed toepassen van aanvullende 
klierdissecties mogelijk kunnen maken, en daarmee onnodige morbiditeit en kosten besparen. 
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 Momenteel lopende internationale trials onderzoeken alternatieve behandelingsopties voor 
schildwachtklier-positieve patiënten. De tweede Multicenter Selective Lymphadenectomy Trial (MSLT-
II) van Morton et al.5 vergelijkt directe aanvullende klierdissectie met echografische observatie van het 
klierstation en uitvoeren van een therapeutische lymfeklierdissectie wanneer er lymfekliermetastasen 
aan het licht komen. De EORTC MINITUB registratie studie6 onderzoekt het effect van het achterwege 
laten van een aanvullende klierdissectie bij patiënten met minimale tumorload in de schildwachtklier. 
 Als de MSLT-II studie laat zien dat directe aanvullende klierdissectie beter is dan observatie van 
het klierstation, dan zou patiëntselectie voor deze therapie de behandeling van schildwachtklier-
positieve patiënten kunnen verbeteren. Combinatie van verschillende voorspellers van non-
sentinelnode positiviteit zal de meest accurate selectie opleveren, ongeacht of het doel is patiënten te 
selecteren voor het uitvoeren of juist voor het afzien van aanvullende klierdissectie. 
 De bruikbaarheid van de biomarkers S-100B en Lactaat dehydrogenase (LDH) voor deze 
patiëntselectie werd onderzocht in Hoofdstuk 4. In dit hoofdstuk staat beschreven dat de biomarker 
S-100B een sterke voorspeller is van non-sentinel node positiviteit en derhalve risico scores voor non-
sentinel node positiviteit kan aanvullen. Op deze manier kunnen schildwachtklier-positieve patiënten 
met een laag risico worden geselecteerd om hen een aanvullende klierdissectie te besparen. 
Schildwachtklierprocedure 
De schildwachtklierprocedure is algemeen geaccepteerd als een belangrijke prognostische procedure 
voor melanoompatiënten met een melanoom dikker dan 1 mm Breslowdikte. Het uitvoeren van de 
schildwachtklierprocedure met aanvullende klierdissectie in geval van een positieve schildwachtklier 
lijkt zelfs een overlevingsvoordeel op te leveren ten opzichte van echografische controle van het 
lymfeklierpakket en therapeutische lymfeklierdissectie wanneer er een metastase wordt gevonden.7 
Ondanks deze capaciteiten blijkt uit Hoofdstuk 5 dat 75% van de Nederlandse medisch specialisten 
van mening zijn dat de schildwachtklierprocedure niet behoort tot de standaard diagnostiek van het 
melanoom. Zij conformeren zich aan de inhoud van de Nederlandse Richtlijn Melanoom uit 2005, 
waarin staat dat de schildwachtklierprocedure dient te worden gereserveerd voor patiënten die 
optimaal geïnformeerd willen worden over hun prognose en dat deze procedure geen deel uitmaakt van 
de standaard diagnostiek. Aanpassing van zowel de nationale richtlijn als de houding van Nederlandse 
medisch specialisten is noodzakelijk, zeker als lopende studies een echt overlevingsvoordeel laten zien 
van deze procedure.
Follow-up 
De prevalentie van melanoompatiënten blijft stijgen door de stijgende incidentie van het melanoom en 
verbeterde behandelingsresultaten. Dit heeft geleid tot een stijgende vraag naar zorgmiddelen rondom 
het melanoom, met steeds meer melanoompatiënten die behandelingen en follow-up nodig hebben.8 
De frequentie van follow-up van melanoompatiënten is sinds lange tijd een groot discussiepunt 
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doordat wetenschappelijke data ontbreken en internationale studies op dit thema niet bestaan. In de 
landen met de hoogste melanoomincidentie wordt momenteel een hoogfrequent follow-up schema 
aanbevolen.9 In Hoofdstuk 5 werd onder andere de mening van Nederlandse medisch specialisten 
over follow-up onderzocht. Dit hoofdstuk laat zien dat de intensiteit van hoogfrequente follow-up 
schema’s, zoals geadviseerd door de Nederlandse richtlijn uit 2005, zou kunnen worden verminderd 
volgens een groot deel van de Nederlandse medisch specialisten. Het reduceren van de intensiteit 
van follow-up schema’s zou bijdragen aan het oplossen van de toenemende zorgvraag rondom het 
melanoom. 
 Om wetenschappelijke onderbouwing te verkrijgen voor nieuwe follow-up schema’s voor 
melanoompatiënten onderzoekt het Universitair Medisch Centrum Groningen de toepasbaarheid en 
veiligheid van een gereduceerd follow-up schema in de lopende MELFO trial.10, 11
Lymfekliermetastasen 
De regionale controle en overleving van melanoompatiënten die een klinisch detecteerbare 
lymfekliermetastase ontwikkelen kan worden verbeterd door het uitvoeren van een zogenaamde 
therapeutische lymfeklierdissectie met of zonder adjuvante radiotherapie.12-17 Ondanks nauwkeurige 
preoperatieve stadiëring met behulp van een PET en/of CT scan blijft de 5-jaarsoverleving van deze 
patiëntencategorie teleurstellend: 29-52%. In Hoofdstuk 6 werd aangetoond dat de anatomische 
lokalisatie van de lymfekliermetastase een belangrijke voorspeller is van de prognose na een 
therapeutische lymfeklierdissectie. Patiënten die een therapeutische lymfeklierdissectie ondergaan 
voor een metastase in de hals, hebben een betere melanoomspecifieke overleving dan patiënten met 
een metastase in de oksel of lies. 
 Voortbordurend op eerdere studies die de prognostische waarde van de biomarker S-100B 
hebben aangetoond18, is in Hoofdstuk 7 de prognostische impact van de biomarkers LDH en S-100B 
vergeleken en de optimale timing van hun meting onderzocht bij stadium IIIB-C melanoompatiënten. 
Preoperatief gemeten S-100B bleek, in tegenstelling tot LDH, één van de belangrijkste voorspellers 
van de prognose bij stadium IIIB-C melanoompatiënten die een therapeutische lymfeklierdissectie 
ondergingen. 
 Het includeren van S-100B in de huidige melanoomclassificatie zou leiden tot betere stadiëring 
van melanoompatiënten met lymfekliermetastasen. Bovendien kunnen melanoompatiënten die 
belast zijn met een slechte prognose,  voorspeld door een preoperatief verhoogd S-100B level, worden 
geselecteerd voor nieuwe trials met (neo)adjuvante therapie met nieuwe systemische middelen zoals 





Stadium IV melanoom is nog altijd moeilijk te genezen en deze patiënten met afstandsmetastasen 
hebben een zeer slechte prognose. Tot op heden lijkt chirurgische resectie de enige behandelmodaliteit 
die curatie kan bewerkstelligen. In een geselecteerde patiëntencategorie waarbij complete resectie van 
alle metastasen mogelijk is, lijken de overlevingscijfers dan ook bemoedigend. Echter, zoals Hoofdstuk 
8 laat zien, komt minder dan 10% van alle stadium IV patiënten in aanmerking voor complete resectie 
van alle afstandsmetastasen. Dus als toekomstige studies de superioriteit van complete chirurgische 
resectie boven systemische medische therapieën zouden aantonen, zou dit alleen van toepassing zijn 
op een zeer klein deel van alle stadium IV patiënten. De overige patiënten die niet in aanmerking 
komen voor complete chirurgische resectie blijven afhankelijk van nieuwe successen die mogelijk 
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Rising incidence and costs
From an epidemiologic point of view, it is expected that the incidence of cutaneous melanoma will 
continue to rise in most countries.1 In the Netherlands, not only the incidence of thin melanomas is 
steadily increasing, but also thick melanomas will be more frequently diagnosed in the upcoming years. 
It has been estimated that this increasing incidence will result in 5400 newly diagnosed melanomas in 
2020, compared to 4665 in 2010. The prevalence of melanoma patients is therefore thought to be 1.5 
times higher in 2020, entailing a significant rise in health care costs. In addition, the number of annual 
melanoma associated deaths is expected to rise from 783 in 2010 to 970 in the year 2020. 2, 3
 To combat these worrying incidence trends, primary prevention is most effective. Therefore, 
the importance of sun-protective behavior in skin cancer prevention, especially for children and 
adolescents, has already been propagated for a couple of decades. More recently, a growing number 
of population-based studies report an association between tanning bed use in young people and risk 
for melanoma.4-6 Reducing tanning bed usage through strict legislation, as is already implemented in 
some countries, could flatten the rise in melanoma incidence and the entailing health care costs. 
 Restraining the rise in costs for melanoma care could possibly be obtained by better patient 
selection for surgical procedures like lymph node dissections and increasing their cost-effectiveness, 
for instance by reducing bed rest regimens as described in this thesis. The pending MELFO trial7, 8 
studies whether less intensive follow-up schedules for melanoma patients are feasible and safe. If so, 
this can create a significant reduction in the costs of melanoma care. 
Prediction of outcome and patient selection
Today’s attempts to gain progression in surgical oncology are not only focused on improving the 
quality of surgical procedures, but increasingly on prediction of outcome based on risk profiles and 
patient selection. As was shown in Chapter 3 and 4 of the present thesis, completion lymph node 
dissection (CLND) seems to be overtreatment in about 80% of sentinel node (SN)-positive patients. 
In the future, predictive risk scores will become more and more important to decide whether 
treatments, like CLND, will be beneficial for the outcome of the individual patient. Biomarkers, like 
the melanoma biomarker S-100B, will be increasingly used in such risk scores, as they can provide 
important prognostic information. In addition, pending research is studying whether more details 
encoded in the (expression of) DNA in melanoma cells could be used for the prediction of outcome 
following systemic treatments.  
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Future perspectives
Sentinel lymph node biopsy
Now that the follow-up of the first Multicenter Selective Lymphadenectomy Trial (MSLT-I) is completed, 
we will soon be informed about whether performance of sentinel lymph node biopsy (SLNB) improves 
patient survival compared to watchful waiting with ultrasound in patients with melanomas with 
Breslow thickness > 1 mm. Following the results of the last interim analysis, we expect a modest 
survival benefit after ten years of follow-up in patients who underwent SLNB.9 
 For patients with thin melanoma (< 1 mm Breslow thickness), the prognosis is not very likely 
to improve through SLNB because their survival is already very good and the rate of sentinel node 
positivity in these patients is very low. SLNB for thin melanoma in highly selected patients showed 
8% SN positivity10. New studies will focus on the prognostic impact and survival influence of SLNB in 
patients with thin melanomas especially for melanomas with a Breslow thickness between 0.75 and 1 
mm. 
Nodal dissections  
Besides moving to even further reduced bed rest regimens to increase patient comfort and cost-
effectiveness of the groin dissection, a future approach that is currently being explored encompasses 
laparoscopic groin dissection in an attempt to reduce the rate of wound complications.11 
New systemic therapies 
Recently, a revolution is initiated by the introduction of two systemic drugs showing promising 
response rates in stage IV melanoma patients: ipilimumab, an anti-CTLA4 antibody, and vemurafenib, 
a selective inhibitor of the BRAF signaling pathway. Future research in stage IV melanoma patients will 
focus on simultaneous blockage of different signal transduction pathways to increase the durability of 
the therapeutic responses. A recently opened trial combines BRAF inhibition with MEK inhibition for 
this purpose12.
 Moreover, these new systemic medical agents will soon be tested as adjuvant therapy in 
curatively treated patients. The upcoming COMBI-AD trial will study the effect of a BRAF inhibitor 
combined with an MEK inhibitor on relapse-free survival in BRAF-mutation positive patients with stage 
IIIB-C and even IIIA melanoma.13 Prognostic factors like S-100B, as described in this thesis, can improve 
patient selection for administration of these potentially harmful and expensive drugs in adjuvant 
setting. If these adjuvant treatments proof to be effective, these therapies could even replace CLND in 
sentinel node positive patients in the future. 
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